Introduction {#Sec1}
============

Pemphigus vulgaris (PV) is a chronic, autoimmune, mucocutaneous, vesiculobullous disease \[[@CR1]\].

The word pemphigus comes from the Greek word *pemphix*, which means blister \[[@CR2]\]. It is a rare disease with estimated worldwide annual incidence of 0.1--0.5 per 100,000 \[[@CR3]\]. It occurs in all racial and ethnic groups with the highest incidence seen in Ashkenazi Jews \[[@CR4]\]. Occurrence is most common during the fifth and sixth decades of life, although a few cases have been reported in children \[[@CR5]\].

In the majority of cases, PV initially presents with lesions on the oral mucosa \[[@CR3]\]. Often the first sites affected are those exposed to frictional trauma including the buccal and lateral tongue mucosa along the occlusal level, or the gingiva, but PV can occur on any oral site particularly if exposed to sharp or acidic foods. The lesions start as vesicles which rupture easily leaving erosions and ulcers.

The pathogenesis of pemphigus involves the presence of circulating and tissue-bound autoantibodies to the keratinocyte cell surface desmosomal molecules desmoglein 3 (Dsg3) and desmoglein 1 (Dsg1). Dsg3 and Dsg1 belong to the cadherin superfamily involved in cell--cell adhesion. These autoantibodies cause loss of cell--cell adhesion between epithelial cells, which results in suprabasilar intraepithelial vesicle formation \[[@CR4], [@CR6]\].

Diagnostic tests include perilesional mucosal or skin biopsy for histologic examination and direct immunofluoresence testing. Histologic findings include presence of intraepithelial blisters and suprabasilar acantholysis; direct immunofluorescence findings include IgG deposits and less commonly IgM and C3 deposits in intercellular spaces in the epithelium. Blood tests include ELISA testing for Dsg3 and Dsg1 autoantibodies \[[@CR7]\].

Prior to availability of corticosteroid therapy in the 1950s, PV had a very high fatality rate. While many treatment options are now available, corticosteroids in combination with other drugs still form the mainstay of treatment. Mortality from pemphigus has decreased significantly in the last half century and is now usually due to adverse effects of the medications used \[[@CR8], [@CR9]\].

As a result of the relative rarity of pemphigus, there are very few randomized controlled trials. However, numerous observational studies, case reports, and case series have been published that report on the treatment of pemphigus. The objective of this review was to summarize the findings from all of the reported human studies including observational studies and case reports.

Methods {#Sec2}
=======

Publications relating to treatment of PV were identified by searches of electronic databases including PubMed, Cochrane, and Google Scholar through May 2015. Keywords used included pemphigus vulgaris, autoimmune vesiculobullous disease, corticosteroids, azathioprine, rituximab, mycophenolate mofetil, methotrexate, and IVIg. The full-text versions of the papers identified were obtained. The bibliography of these papers was also reviewed to identify any additional papers that did not appear in the electronic search. Only English-language papers describing treatment outcomes of patients with PV were included in this review. A total of 89 papers, which included 21 case reports, 47 case series, 8 RCTs, and 13 observational studies, were included. These papers were reviewed to obtain information on publication date, type of study done, age of the patients, extent of lesion involvement (skin and mucosa), previous treatments if any, medications used, duration of use of previous medications before new ones were started, duration to first improvement after the start of medications, follow-up duration, concomitant medication used along with main drug, outcome, duration on medication, adverse effects of drugs, and antibody titer changes after treatment. This information is summarized in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}.Table 1CorticosteroidsAuthor/yearType of study*N*\
M/FAge at the beginning of follow-up period Range/mean (years)Type of pemphigus vulgarisPrevious RxDuration of disease symptoms before CS were startedCS dose1234567Ryan \[[@CR40]\]/1972Case series*N* = 41 \
M/F = 23/1826--80MucocutaneousNMNM500--1000 mg cortisone equivalentsBerger et al. \[[@CR41]\]/1973Case report1/M3.5Oral mucosal lesionsNMNMPrednisone = 15--120 mg/dayRosenberg et al. \[[@CR42]\]/1976Case series*N* = 85 PV + 5 P vegetans14--88Oral mucosa = 80, Skin = 52NMNMPrednisone = 60--180 mg/dayLozada, Silvermann, Cram \[[@CR14]\]/1982Case series*N* = 6 \
M/F = 3/324--89Mucocutaneous = 6PredNMPrednisone = 40--80 mg/dayLever and Schaumburg-Lever et al. \[[@CR12], [@CR13]\]/1984Case series*N* = 8420--79/mean = 51MucocutaneousNMNMPrednisone = 40--350 mg/dayAberer et al. \[[@CR43]\]/1986Case series*N* = 29 M/F = 12/17At onset of disease---mean 59.9 ± 9.0 years\
At initiation of therapy---61.6 ± 8.1 yearsMucocutaneousPred, MTXNMPrednisone = 80--200 mg/daySeidenbaum et al. \[[@CR44]\]/1988Case series*N* = 88 PV + 27 (PF, PE, P vegetans)\
M/F = 46/6940--60Oral mucosa = 50; Cutaneous = 33; Mucocutaneous = 32NMNMPrednisone = 60--120 mg/dayDavid et al. \[[@CR15]\]/1988Case series*N* = 4 \
M/F = 2/211--17Mucocutaneous = 3, Oral mucosa = 1NMNMPrednisone = 60--80 mg/dayLaskaris and Stoufi \[[@CR45]\]/1990Case report1/F6Extensive oral mucosal lesionsNone as no diagnosis was made when symptoms were first noted at age of 24Prednisolone = 30 mg/day for 3 weeks. Prednisolone maintained to 10 mg/day every other day after clinical improvementLamey et al. \[[@CR16]\]/1992Case series*N* = 30 \
M/F = 10/2024--68/Mean = 48.1Cutaneous = 4; Mucosal = 26 (Oral mucosa = 25)NM2--9 mo (Mean = 3.5 mo)Prednisone = 20--120 mg/day in 29 pts. No Rx in 1 ptWerth \[[@CR46]\]/1996Retrospective case controlled study*N* = 15 \
M/F = 10/528--72Mucosal = 6; Cutaneous = 1; Mucocutaneous = 8NoneMean. Control grp = 3.1 ± 1.2 mo; Pulsed grp = 4.1 ± 1.0 moControl grp (*N* = 6)\
Pulsed grp (*N* = 9). Methylprednisolone sodium succinate pulsePred = 95 ± 22.5 mg\
Pred before pulse = 82 ± 15.8, after pulse = 78 ± 7.6 mg/d. Pulse dose = 250--1000 mg/24 hRobinson et al. \[[@CR47]\]/1997Case series*N* = 12 \
M/F = 3/93--66/Mean = 32Oral mucosa = 12, Cutaneous = 7NMNM (Newly diagnosed pts)Prednisone = 10--80 mg/dayKaur and Kanwar et al. \[[@CR17]\]/1990Case series*N* = 45 PV + 5 PF\
M/F = 24/2115--55NMNM3 mo to 5 yearsDexamethasone = 136 mg dissolved in 5 % dextrose given by a slow iv drip over 1--2 h and repeated on 3 consecutive daysMignogna et al. \[[@CR48]\]/1999Retrospective analysis*N* = 16 \
M/F = 5/1126--76/Mean = 51Oral mucosa = 16, Cutaneous = 6NM1--3 mo (Mean = 55 days)Deflazacort = 120 mg/dailyScully et al. \[[@CR49]\]/1999Case series*N* = 32, Additional 23 pts referred to dermatology and with limited available data\
M/F = 22/2316--83/Mean = 50.2Mucosal = 55, cutaneous lesions later developed = 13NM3--192 weeks (Mean = 27.2 weeks) from 42 patients with available dataPrednisolone = 20--80 mg/dayHerbst and Bystryn et al. \[[@CR29]\]/2000Case series*N* = 40 \
M/F = 15/2514--73/Mean = 51MucocutaneousNMNMPrednisone = 15--90 mg/dayKanwar et al. \[[@CR18]\]/2002Retrospective analysis*N* = 3221--75/Mean = 49Mucocutaneous = 27; Mucosal = 1; Cutaneous = 4NMNM136 mg iv Dexamethasone for 3 consecutive days (2--8 pulses required for PR) and (8--32 pulses required for CR) + 500 mg CyclP on day 2Ljubojevic et al. \[[@CR50]\]/2002Retrospective analysis*N* = 154 \
M/F = 57/9719--89/Mean = 53MucocutaneousNM\>5 yearsPrednisone = 100--150 mg daily for first 4--6 weeks. Then gradually tapered to maintenance dose of 5--20 mg. In 14 pts with refractory PV I.M. gold given up to 50 mg per weekFemiano et al. \[[@CR51]\]/2002Case series*N* = 20 \
M/F = 8/1235--57/Mean = 43MucocutaneousNMNMOral Pred (*N* = 10)\
125 mg/day to 5 mg once a week for 1 mo\
Oral Pred alternated with iv betamethasone (N = 10)\
Pred 50 mg/day to 5 mg/d once a week for 1 week/20 mg/d iv to to 8 mg/d iv for 4 daysRobinson et al. \[[@CR32]\]/2004Case report1/M47Oral lesionsNM3 moPrednisolone = 1 mg/kg/day (80 mg); topical 0.1 % triamcinolone acetonideChams davatchi et al. \[[@CR38]\]/2005Case series*N* = 1111 M/F = 492/7174--82/Mean = 42Mucocutaneous = 782; Mucosal = 200; Cutaneous = 129. Oral cavity involved in 978 ptsNoneNMPrednisone dose NMAlonso et al. \[[@CR33]\]/2005Case series*N* = 14 \
M/F = 4/1021--87Oral mucosa = 9; Mucocutaneous = 5NM0.75--72 mo (Mean = 11.66 mo)0.5 % Triamcinolone corticosteroids + 60 mg/day systemic Pred in 12 pts for 1 mo/Intralesional corticoid infiltration (parametasone) in 1 pt every 15 days during 45 days of therapyBen lagha et al. \[[@CR31]\]/2005Case report1/F71MucocutaneousNM4 moPrednisone = 0.5 mg/kg/d; 20--40 mg/dayAriyawardana et al. \[[@CR5]\]/2005Case report1/F14Oral mucosal lesionsNone10 daysSystemic Prednisolone = 10 mg/day; 0.1 % triamcinolone acetonide in orabase twice a day maintenance dose for 3 moYazganoglu et al. \[[@CR39]\]/2006Case series*N* = 5 \
M/F = 3/27--15 yearsMucocutaneousNMNMPrednisolone = 1--2 mg/kg/dayMentink et al. \[[@CR19]\]/2006Randomized controlled trial*N* = 20 \
M/F = 13/726--71/Mean = 49MucocutaneousSystemic and topical CS, AZA, antibioticsNMDP (Dexamethasone pulse therapy) (*N* = 11)\
Oral dexamethasone in 300 mg pulses 3 days/mo, 5.44 pulse coursesPP (placebo pulse therapy) (*N* = 9)\
6 Placebo tablets 3 days/mo, 6.44 pulse coursesChaidemenos et al. \[[@CR52]\]/2007Prospective cohort study*N* = 74 Studied = 68 \
M/F = 21/4724--83 yearsOral mucosa = 68; cutaneous = 33; genital and nasal lesions = 14NM0.15--18 mo/mean = 3.6 moPrednisone = 40 mg/dayChams davatchi et al. \[[@CR53]\]/2007Randomized controlled open label trial*N* = 120 M/F = 71/40Mean = 40 yearsMucocutaneous = 74; mucosal = 29; cutaneous = 8. Oral cavity involved in 76 ptsNone3--12 mo/1 yearMean total dose (P = Prednisolone)\
Pred (30)\
11631 mg (2 mg/kg/day)\
Pred/AZA (30)\
7712 mg (2 mg/kg/day P + 2.5 mg/kg/day AZA\
Pred/MMF (30)\
9798 mg (2 mg/kg/day P + 2 g/d MMF)\
Pred/CyclP (30)\
8276 mg (2 mg/kg/day P + 1 g iv CyclP monthly)Dagistan et al. \[[@CR30]\]/2008Case report1/F35Oral lesionsSultamisilin, flurbiprofen2 moPrednisolone = 80 mg/day initially for 14 days and increased to 100 mg for a period of 14 daysTran et al. \[[@CR54]\]/2013Retrospective chart*N* = 23 \
M/F = 11/1226--72/Mean = 54Mucosal = 19, cutaneous = 4Pred, AZA, MMF, dapsone, Rtx, IVIg, etanercept, chlorquine2 mo to 10 years (Mean = 23 mo)Prednisone = 35 mg/daily (mean dose)Mignogna et al. \[[@CR55]\]/2010Case series*N* = 35 \
M/F = 13/2217--72/Mean = 45Oral pharyngealNMNMTotal CS + immunosuppressive therapy + PITAinjections (*N* = 16)\
4894 mg (75--100 mg/day) + 2--8 sessions of PITA injectionsTotal CS + Immunosuppressive therapy only (*N* = 19)\
5312 mg (75--100 mg/day)Author/yearDuration to initial improvement in symptoms after CSFollow up periodConcomitant RxOutcomeDuration on medication (corticosteroid) and adjunct^a^PV antibody titer changes after RxAdverse effects891011121314Ryan \[[@CR40]\]/1972NMVariable F/U periods, maximum = 20 yearsMTX, Mechlorethamine hydrochlorideDeath = 24 pts; CR off = 5 which lasted for 2--156 mo before relapse; 11 pts were on long term medication with occasional flares; Lost to follow-up = 11--18 yearsNMDM, Cushingoid features, furuncles, hyperkalemia, osteoporosis, melena, purpura, hypocalcemia, acidosis, electrolyte imbalance,phlebitisBerger et al. \[[@CR41]\]/1973NM7.5 yearsNonePatient was treated with prednisone intermittently during the f/u period. Controlled activity of disease at the last f/u visit6.5 yearsIIF was positive intercellularly at 1:10 before and after treatmentCushingoid, retarded bone age, osteoporosis of long boneRosenberg et al. \[[@CR42]\]/1976NM1 to \>15 yearsAZA or MTX in 3 ptsDeath related to PV or drug = 28; Death unrelated to PV = 9\
48 survivors. Many d/c therapy and fewer required 15 mg of PredNMNMCushingoid symptoms, Infections, GI tract ulceration, CHF, HTN, Diabetes, Osteporosis, thromboembolic phenomenon, etcLozada, Silvermann, Cram \[[@CR14]\]/19822--8 weeks9--27 monthsLevamisole = 100--200 mg/weekSymptoms of pain resolved = 6, PR (oral lesions) = 3, PR (skin lesions) = 2, CR (oral lesions) = 3, CR (skin lesions) = 41.5--13 yearsNMChills, malaise which disappeared on d/c levamisole and did not recur on restartLever and Schaumburg-Lever et al. \[[@CR12], [@CR13]\]/1984NM5--22 yearsAZA, MTX in 3 pts which was replaced by AZADeath = 15; still being treated = 11; CR off = 47; CR on = 115 months to 8 years in CR off ptsNMNo significantAberer et al. \[[@CR43]\]/1986NM4--16 years (29 Pts)AZA = 2--3 mg/kg body weightStill being treated = 5; CR on = 11 pts, mean duration of Pred use before taper to low dose was 6 months (10 mg QOD); CR off = 13 pts, mean duration of F/U after d/c of medication was 4 years without relapseAZA tapered to 1--2 mg/kg in 6 months. Pred and AZA D/c in 13 pts after maintenance therapy from 6 months to several years. Mean duration of therapy = 6.9 ± 3.8 yearsAntibody titers before treatment were \>160 monitored by IIF. After treatment: Negative in 13 CR off pts. \>80 in 6 pts despite good clinical responseLeukopenia, herpes simplex, bacterial infectionSeidenbaum et al. \[[@CR44]\]/1988NM4--24 yearsAZA 100--150 mg/dayDeath = 25 (11 PV) Still treated = 45, CR on = 10, CR off = 35NMNMNMDavid et al. \[[@CR15]\]/19881 months4--19 yearsNoneCR on = 1, mean duration of Pred use before taper to low dose was 4 years after 2 relapses. CR off = 1 within 1 year of medication, mean duration of f/u after d/c of medication was 6 years without relapse. CR off = 1 within 1 mo of medication, mean duration of f/u after d/c of medication was 4 years without relapse. (PR = 1 on homeopathy, did not take Pred)Rx d/c in 2 pts after CR in 1 mo and 1 years after gradually tapering PredNMNMLaskaris and Stoufi \[[@CR45]\]/1990NMLost to follow up after 2 yearsNoneClinical improvement2 years until last f/u. Pred tapered and maintained to 10 mg/day from 30 mg/dayNMNMLamey et al. \[[@CR16]\]/19924--8 weeks5--20 yearsAZA, Cyclp in 3 pts. Gold in diabetes mellitus ptCR on = 27 within 4--8 weeks of start of therapy. Pred tapered to 10 mg/day or on alternate days in other patientsNMNMDiabetes mellitus, HTN, duodenal ulcersWerth \[[@CR46]\]/1996NMAt least 500 daysAZA, MTX, CyclP, Dapsone, GoldPulsed grp: Improvement = 6, CR off = 4 within mean 269 days of start of therapy and mean duration of f/u after d/c of medication was 714 days without any relapses Control grp: No remission in any 6 ptsNMNMWell tolerated. Transient increase in blood glucose levels treated successfully with insulinRobinson et al. \[[@CR47]\]/1997NM8--11 years (Mean = 4.5)AZA, levamisole, cyclosporine, MTX, dapsone, topical dexamethasone, fluocinonide, clobetasol, clotrimazolePR on = 3; CR on = 9, within 1.5--42 mo of start of therapyAll pts were on medication at the end of f/uNMCushingoid symptoms, Infections, GI upset, weight gain, fatigue, mood changes, constipation, osteoporosis, diabetes, insomnia, acute psychosisKaur and Kanwar et al. \[[@CR17]\]/19903--4 days2 yearsCyclP 500 mg added to dexamethasone and 50 mg orally each day, Pred (30--40 mg) in 7 ptsStill being treated = 28; death due to septicemia = 3 pts; lost to F/U = 13; no improvement & hence Rx changed = 6All pts were on medication at the end of f/uNMCardiac arrhythmia in 1 pt and Ischemic heart disease in 1 ptMignogna et al. \[[@CR48]\]/1999NMNMAZA = 50--100 mg/d or CyclP = 50 mg dailyPR within 2--8 weeks of start of therapy = 14, CR off = 21--8 yearsNMCushingoid symptoms, Infections, GI upset, weight gain, fatigue, mood changes, constipation, diabetes, osteoporosis, insomnia, psychosisScully et al. \[[@CR49]\]/1999NMAt least 3 monthsAZA (1--3 mg/kg/day), MTX, CyclP, dapsoneDeath = 2, Relapses and still being treated at time of publication = 21, PR on = 4, CR off = 5pts within 3 mo of start of therapy. (NM whether on or off of therapy)NMNMLethargy, cushingoid faces, adrenal suppression, candidiasis, HTNHerbst and Bystryn et al. \[[@CR29]\]/2000NM2--19/Mean = 7.7 yearsAZA, CyclP, dapsone, gold, cyclosporine, PlDeath = 2; PR = 8; CR off = 30, within 18--35 mo of start of therapyRx for 2--19 years (mean = 7.7 years)NMNMKanwar et al. \[[@CR18]\]/2002NM2--12 years (Mean = 4.2)50 mg orally each day, PredCR off = 32 within 20--32 mo (Mean = 24 mo) of start of therapy1 year (Pulse therapy for 6 mo followed by oral CyclP 50 mg orally for 1 yearNMHTN, pulmonary tuberculosis, leucopenia, diarrhea, cataract, oligomenorrhea, sinus bradycardiaLjubojevic et al. \[[@CR50]\]/200219 yearsNMAZA (100--150 mg); Pl in 5 pts with NR to AZA and PredDeath = 14; PR on = 15; CR off = 5, mean duration of f/u after d/c of therapy was 5 mo to 5 years without relapse. Complications due to Pred, Rx d/c = 74, lost to follow up = 46NMNMSepsis, arterial HTN, cardiorespiratory diseases, skin infectionsFemiano et al. \[[@CR51]\]/2002NMNM150 mg/d Ranitidine, 1 ml Nystatin suspension bidOral PredPred/iv bmsNMNMGastritis, hyperglycemia, HTN, increased body weight, mood change, altered Ca and P levelsSymptom resolved15 d12 dClinical resolution30 d25 dRobinson et al. \[[@CR32]\]/20042 weeks8 moCimetidine, nystatin, calcium supplementsCR on within 3 mo of start of therapyPred tapered over 8 mo to 10 mg/dayNMNoneChams davatchi et al. \[[@CR38]\]/2005NM3.8 years, lost to F/U = 200MMF/AZA, CyclP/Gold/DapsoneDeath = 66; Still being treated = 350; Maintenance Rx = 471; CR off = 112 (Nothing else mentioned about duration to achieve remission and duration on medication)Mean 4.5 yearsNMCandidiasis, HTN, osteoporosis, abnormal liver function test, infection, diabetes mellitusAlonso et al. \[[@CR33]\]/2005NMNMNoneImprovement in all pts. Additional details were NM45 daysNMNMBen lagha et al. \[[@CR31]\]/2005NM12 moMTX 10--20 mg/weekCR on within 9 mo of start of therapy. Therapy was stopped at sixth mo after starting Pred and resumed after healing of fracture of femurRx contd at dose of 10 mg/d at the end of f/uNMStress fracture in neck of femurAriyawardana et al. \[[@CR5]\]/20051 mo12 moDapsone 100 mg/dayCR off within 4 mo of starting therapy. No relapsesSystemic Pred. d/c at 1 mo and topical d/c in 3 mo after thatNMNMYazganoglu et al. \[[@CR39]\]/2006NM4 pts were followed for 2--4 years. 1 patientt was lost to F/UMMF in1 patient, dapsone in 1 patientRelapses in all 4 cases which were controlled with Pred and MMF in 1 caseTreatment continued in all pts at end of f/uNMCushingoid appearance and acneiform eruption in 2 ptsMentink et al. \[[@CR19]\]/200619 wks in 4 DP and 6 PP pts1 yearAZA = 3 mg/kg/day, Pred = 80 mg/dayCR on = 8 in DP within 173.2 days of starting therapy, CR on = 9 in PP within 175.6 days of starting therapyPred tapered to 0 from 80 mg/day over 19 weeks and treatment was given for 1 yearNMWeight gain, increased blood glucose, wound infection, HTN, candidiasis, myopathy, diarrhea, leukopenia etcChaidemenos et al. \[[@CR52]\]/2007NM26--180 moAZA (100 mg/day)Death = 2; CR on = 57, mean duration of f/u after d/c of medication was 27 ± 29 mo without relapses; Dropped out = 6; Rx changed = 9;2--138 mo. In 6--14 mo Pred tapered at a rate of 5 mg/mo and AZA tapered until 0 in 1 yearNMTuberculosis reactivation, toxic hepatitis, bone marrow depression, disturbed WBC countsChams davatchi et al. \[[@CR53]\]/2007NM1 year\
Nine were lost to F/UMMF, AZA, CyclPCR on; failures; complications (Rx d/c)Duration on Rx = 1 year Tapering of Pred started in mean 17.2 ± 7.2 days until it was reached 7.5 mg/dayNMCandidiasis, hyperlipidemia, herpes simplex, hyperglycemia, fungal and viral skin infections, gastritis, cataract, psychosis, infectionsPred23, 6, 1Pred/AZA24, 1, 2Pred/MMF21, 8, 1Pred/CyclP22, 2Dagistan et al. \[[@CR30]\]/2008NM1 yearAZA 50 mg twice a dayCR on (Additional details NM)Pred tapered at end of 7 weeks by 30 mg/day. Treatment lasted for 1 yearNMHepatitis CTran et al. \[[@CR54]\]/2013NMNMMean MTX = 18.9 (15--25) mg/weekRx d/c in 2 due to adverse events. Lost to f/u = 4, Still being treated = 4; clinical improvement in 21 pts of which pred d/c in 16 pts. CR off = 3, mean duration of f/u after d/c of medication = 26 mo until end of f/uPred d/c in mean 18 mo in 16 pts. In other five patients low dose pred in range of 2--10 mg/day was given. MTX d/c in 3 pts and tapered in 8 ptsNMFatigue, GI side effectsMignogna et al. \[[@CR55]\]/2010NMMean = 5.3 yearsPITA grp: AZA 50--150 mg/day; CyclP 50--100 mg/day. No PITA grp: AZA 100 mg/day; CyclP 50 mg/dayDeath 3 years after CR = 1; CR on = 21; CR off = 13; complete clinical remission within mean 126.6 days of starting therapy in grp with PITA. Complete clinical remission within mean 153.2 days of starting therapy in grp without PITANMNMCandidiasis in 3 pts, yellowish gingival pellets, gingival neurovascularization in PITA pts. Candidiasis in 7 pts without PITA*Pred* prednisone, *CS* corticosteroid, *MMF* mycophenolate mofetil, *AZA* azathioprine, *MTX* methotrexate, *DCP* dexamethasone cyclophosphamide pulse, *IVIg* intravenous immunoglobulin, *Rtx* rituximab, *CyclP* cyclophosphamide, *Pl* plasmapheresis, *CR off* complete remission off therapy, *CR on* complete remission on therapy, *PR* partial remission, *R* relapse, *F/U* follow-up, *d/c* discontinue, *mo* months, *wks* weeks, *d* days, *NM* not mentioned, *PITA* perilesional/intralesional triamcinolone acetonide^a^Duration on medication included the time period on medication prior to the start of follow-up to this paperTable 2AzathioprineAuthor/yearType of study*N*\
M/FAge range/mean (years)Type of pemphigus vulgarisPrevious RxDuration of disease before AZAAZA dose, prednisone dose1234567Mourellou et al. \[[@CR56]\]/1995Retrospective analysis*N* = 48NMNMNMNM40--100 mg Pred\>100 mg Pred40 mg Pred + 100 mg AZA25 pts8 pts15 ptsChaidemenos et al. \[[@CR1]\]/2010Retrospective bi center comparative study*N* = 36 \
M/F = 16/20Mean = 54MucosalNM4 moMonotherapy of Pred (*N* = 17)Alternate day Pred + daily AZA (*N* = 19)Starting dose = 1.5 mg/kg/day40 mg Pred every other day + 100 mg/d AZAChams-Davatchi et al. \[[@CR57]\]/2013Randomized double blind controlled study*N* = 56 M/F = 23/3310--75Mucocutaneous = 33; mucosal = 15; cutaneous = 8None5--10 moPlacebo grp (Pred + placebo)AZA grp (Pred + AZA)Pred: 2 mg/kg up to 120 mg/dayPred: 2 mg/kg up to 120 mg/dayPlacebo: 2.5 mg/kgAZA: 2.5 mg/kgAuthor/yearDuration to initial improvement of symptoms after AZAFollow up periodConcomitant RxOutcomeDuration on all medications^a^PV antibody titer changes after RxAdverse effects891011121314Mourellou et al. \[[@CR56]\]/1995NMUp to 10 yearsPredCR off = 5; CR on = 22; death = 12, still being treated = 6, lost to follow-up = 3\
14/15 pts treated effectively in AZA + Pred grp. No deaths in that grpTotal duration on medications NM. Therapy d/c once patient was in remission for 6 moNMNMChaidemenos et al. \[[@CR1]\]/2010Monotherapy grp = mean 19. 2 days;\
Pred + AZA grp = mean 58.53 days24 moPredMonotherapyAlternate day Pred + daily AZA24 mo\
CR and PR on therapy in mean 119.6 days and off therapy in 234.4 daysNMWeight gain, GI disturbances, hair loss, HTN, arrhythmias, eye disease, internal infection, muscle weakness, redistribution of body fat etcPR on3PR on4PR off2PR off2CR on9CR on7CR off1CR off2Death1Death0Rx failure1Rx failure4Chams-Davatchi et al. \[[@CR57]\]/2013NM12 moPredPlaceboAZAMedications given for 5--22 mo.NMAbnormal liver function test, sepsis, abnormal CBCCR on (6--11 months)13CR on (8--11 months)16NR11NR6Dropped4Dropped6*Pred* prednisone, *AZA* azathioprine, *CR off* complete remission off therapy, *CR on* complete remission on therapy, *PR* partial remission, *PR on* partial remission on therapy, *PR off* partial remission off therapy, *R* relapse, *NR* no response, *F/U* follow-up, *d/c* discontinue, *mo* months, *d* days, *pts* patients, *NM* not mentioned^a^Duration on medication included the time period on medication prior to the start of follow-up to this paperTable 3Mycophenolate mofetilAuthor/yearType of study*N*\
M/FAge range/mean (years)Type of pemphigus vulgarisPrevious RxDuration of disease before MMF^a^MMF dose1234567Enk and Knop \[[@CR58]\]/1999Case series*N* = 12 \
M/F = 5/742--64NMPred, AZA4--8 mo2 g/dayGrundmann-Kollmann et al. \[[@CR59]\]/1999Case report1/F76NMPred, AZA7 years2 g/dayGrundmann-Kollmann et al. \[[@CR59]\]/1999Case report1/F66CutaneousPred, AZA2 years2 g/dayPowell et al. \[[@CR21]\]/2002Case series*N* = 12 \
M/F = 4/841--78Mucocutaneous = 8; mucosal = 4AZA, Pred, MTX, CyclP, IVIg, dapsone, gold, thalidomide, minocin6--168 mo750 mg to 3.5 g (Mean = 2.5 g/day)Mimouni et al. \[[@CR60]\]/2003Case series*N* = 31 PV + 11 PF\
M/F = 21/216--74 (Mean = 47.2)NMPred, AZANM35--45 mg/kg per dayS. Beissert et al. \[[@CR61]\]/2006Multicenter randomized controlled non-blinded clinical trialN = 33 PV + 7 PF; 21 PV pts treated with MMF\
M/F = 16/23Mean = 56.5Cutaneous = 39;\
mucosal = 28NMNMMMF = 1 g twice dailyAZA = 2 mg/kg/dStrowd et al. \[[@CR62]\]/2010Retrospective chart review*N* = 18 \
M/F = 8/1029--67/52Mucocutaneous = 12, mucosal only = 6Pred, Pred + MMF in 1 pt only1--6 yrs2--3 g/dayS. Beissert et al. \[[@CR63]\]/2010Multicenter placebo controlled non-blinded trial*N* = 94 \
M/F = 38/56\
75 completed study18--70/45.5MucocutaneousNMMean = 4 moPlacebo + Pred36ptsMMF2 g/d + Pred21 ptsMMF3 g/d + Pred37 ptsBongiorno et al. \[[@CR64]\]/2010Case series*N* = 9 \
M/F = 5/418--75NMPred + AZA14.4 moEnteric coated---mycophenolate sodium 1440 mg/day (given in 2 divided doses)Ionnaides et al. \[[@CR65]\]/2011Randomized prospective non-blinded clinical trial*N* = 36 PV + 11 PF\
M/F = 18/29Mean = 53Cutaneous = 47; oral = 24NMMonotherapy = 4.35 mo; combination = 4.04 moPred alonePred + MMF1 mg/kg1 mg/kg + 3 g/dayAuthor/yearDuration to initial improvement in symptoms after MMFFollow up periodConcomitant RxOutcomeDuration on all medication^b^PV antibody titer changes after RxAdverse effects891011121314Enk and Knop \[[@CR58]\]/1999NM9--12 moPrednisoneCR on = 11 within 2 months of start of therapy; one pt opted out of studyMedication given for 4--20 mo. Pred tapered to median dose of 2.5 mg/day, MMF was contd at last f/uNMMild GI symptoms and mild lymphopeniaGrundmann-Kollmann et al. \[[@CR59]\]/199910 days8 moPrednisoneCR on within 9 weeks of start of therapyTotal duration on medication = 7 years and 8 mo. Pred tapered and stopped after 4 weeks of starting therapy, MMF continued at last f/uNMNoneGrundmann-Kollmann et al. \[[@CR59]\]/19993 weeks8 moNoneCR on within 8 weeks of start of therapyTotal duration on medication = 2 years and 8 mo. MMF continued at last f/uNMNonePowell et al. \[[@CR21]\]/2002Within average 15 mo of therapy27 moPrednisoneStill being treated = 1, flare = 1, opted out = 2, CR on = 4 Controlled = 3, CR off = 1Medication given for 6--195 mo. Pred tapered at 12 and 18 mo. MMF d/c in CR off patient at 24 moELISA: Negative in 5 pts and IIF: Negative in 6 pts after Rx. Gradually decreasing in rest other pts with RxLymphopenia, nausea, depressionMimouni et al. \[[@CR60]\]/2003NM6--49 mo (Mean = 22 mo)PrednisoneRx failure: 8; PR = 1; CR on = 22 within mean 9 mo of start of therapyDuration on medication = mean 22 mo (6--49 mo)Rapid decrease in titersGI symptoms, cytopenia, musculoskeletal painS. Beissert et al. \[[@CR61]\]/2006Within 30 ± 7 days in MMF and AZA grp24 moPrednisone = 2 mg/kg/dailyMMF grp: NR = 1. CR on = 20 within 91 ± 113 days of start of therapyDuration on medication was at least 720 daysNMInfection, dizziness, nausea, diarrhea, blood pressure, hyperglycemia, cushing syndromeAZA grp: Rx d/c due to side effects = 2, NR = 2, lost to f/u = 1, CR on = 13 within 74 ± 127 days of start of therapyStrowd et al. \[[@CR62]\]/201075 % clearance within 1--18 mo (mean = 4.5 mo)Total = 5--130 mo (mean = 35.2 mo); after CR = 1--74 mo (mean = 23 mo)Prednisone = 35--100 mg/day (mean = 60 mg/day)CR on = 14; MMF failed in 4 pts of which Rtx given to 2 of which CR on = 1; CR off = 1; referred elsewhere = 2;\
Total CR off = 3/18 pts eventually after therapyMedications given for 1 mo to 8 years. Pred and MMF d/c in 3 CR off patients after an average 3 years and are in CR for \>than 1 year without relapse. Prednisone and MMF dose tapered with improvement in rest othersNMNMS. Beissert et al. \[[@CR63]\]/2010MMF grpPlacebo grp52 weekPrednisone = 1--2 mg/kg/dayDeath = 1; lost to f/u = 6; NR = 4 due to adverse effects. Rx withdrawn = 22, Improvement in 40/58 pts of MMF combined grp; in 23/36 pts of placebo grpPrednisone dose tapered to 10 mg/day every 4 weeks up to 52 weeksDsg1 and Dsg3 decreased in both grps. Dsg 3 decreased more in placebo grpPyrexia, nausea, cough, oral candidiasis, arthralgia, headache, upper respiratory tract infection24.1 week31.3 weekBongiorno et al. \[[@CR64]\]/201030--45 days18 moPrednisone = 75 mg once dailyNo response = 1. CR on = 6, mean duration of therapy before taper to low dose was 18 mo. CR off = 2 at mean duration of f/u after d/c of therapy was 16 mo without any RMedications given for 32.4 mo. Pred and EC- MPS dose tapered at 6 mo and at 18 mo. Pred was again tapered at 18 mo. EC-MPS was d/c in 2 pts at 16 moReduced Dsg 1 and Dsg 3 in 8/9 ptsHeadache, increased fasting blood glucoseIonnaides et al. \[[@CR65]\]/2011Mean 12 days in monotherapy mean 11.79 days in combination12 moMethylprednisoneMonotherapy: CR on within 144.5 days = 12; CR off within 186.83 days = 6; PR on within 132 days = 2; PR off within 150 days = 3\
Combination: CR on within 141.9 days = 13; CR off within 175 days = 7; PR on within 144.5 days = 2; PR off within 129.6 days = 2Duration on medication was at least 12 mo. MMF and Pred tapered gradually every 2 weeks as per the control of diseases activity. MMF reduced to 2 g/dayNMWeight gain, muscle weakness, fatigue, GI disturbances, glycaemia, HTN, redistribution of body fat, eye disease, Internal infectionMycophenolate used in patients with refractory pemphigus vulgaris (previous treatment with corticosteroids and azathioprine was unsuccessful in achieving remission) are reported in Table [3](#Tab3){ref-type="table"}*Pred* prednisone, *MMF* mycophenolate mofetil, *AZA* azathioprine, *MTX* methotrexate, *IVIg* intravenous immunoglobulin, *CyclP* cyclophosphamide, *Pl* plasmapheresis, *CR off* complete remission off therapy, *CR on* complete remission on therapy, *PR* partial remission, *R* relapse, *F/U* follow-up, *d/c* discontinue, *mo* months, *d* days, *NM* not mentioned^a^Most patients had been previously treated with other medications before MMF was started^b^Duration on medication included the time period on medication prior to the start of follow-up to this paperTable 4Intravenous immunoglobulinAuthor/yearType of study*N*\
M/FAge range/mean (years)Type of pemphigus vulgarisPrevious RxDuration of disease before IVIgIVIg dose1234567Bystryn et al. \[[@CR66]\]/2002Case series*N* = 6 \
M/F = 5/157--78Mucocutaneous = 1; cutaneous = 3; mucosal = 2Pred2 mo to 5 years400 mg/kg/day for 5 days. 1--3 coursesAmagai et al. \[[@CR67]\]/2009Multicenter randomized controlled double-blind trial*N* = 40 PV + 21 PF\
M/F = NMMean: placebo grp = 53.1 yrs; 200 mg grp = 57 yrs; 400 mg grp = 50.1 yrsMucocutaneousPredMean 24 moIV infusion 200 or 400 mg/kg/day in divided doses over 5 days. IV saline for 5 days in Placebo grpPlacebo grp13 pts200 mg grp14 pts400 mg grp13 ptsStojanovic et al. \[[@CR68]\]/2009Case report1/F44NMPred, CyclP3 years400 mg/kg/day for 5 days followed by long term single doses of 400 mg/kg every 6 weeks for 1 yearStojanovic et al. \[[@CR68]\]/2009Case report1/F64NMPred, AZANM400 mg/kg/day for 5 days followed by long term single doses of 400 mg/kg every 6 weeks for 6 moAuthor/yearDuration to initial improvement in symptoms after IVIgFollow up periodConcomitant RxOutcomeDuration on medication (IVIg)^a^PV antibody titer changes after RxAdverse effects891011121314Bystryn et al. \[[@CR66]\]/2002Within 2 wks skin lesions healed by 80 % and oral lesions by 40 %2--4 moPrednisone, CyclP (100--150 mg/day)Controlled disease activity in all 6 pts. Additional details on duration NM.Medications given for 2 mo to 5.4 years. Pred tapered in median 16 days after start of IVIg. 1--3 courses givenIIF: IC IgG Reduced by 72 %. At 2 weeks total IgG reduced to normal levels and 1.7 % below baselineMild stroke in 1 pt with HTNAmagai et al. \[[@CR67]\]/20098--15 daysAfter Rx = 90 days; Total = 2 yearsPrednisone10 pts withdrawn. Significant Improvement in 400 and 200 mg grp pts by day 85. No significant Improvement in placebo group from baseline. Additional details NMUp to 2 yearsELISA: Anti Dsg1 (%): Placebo grp: remained same; 200 mg grp: 100--60; 400 mg grp: 100--60 Anti Dsg3 (%): Placebo grp: 100--75; 200 mg grp: 100--70; 400 mg grp: 100--50 in 90 daysHeadache, hepatitis C, lymphopenia, constipation, nausea, abdominal discomfort, palpitations etcStojanovic et al. \[[@CR68]\]/2009NMNMCyclP, pyridiostigmine bromide for concomitant myasthenia gravisStable Remission^b^1 yearNMNMStojanovic et al. \[[@CR68]\]/2009NMNMPred, pyridiostigmine bromide for concomitant myasthenia gravisStable remission after last infusion^b^6 monthsNMNM*Pred* prednisone, *AZA* azathioprine, *IVIg* intravenous immunoglobulin, *CyclP* cyclophosphamide, *CR off* complete remission off therapy, *CR on* complete remission on therapy, *PR* partial remission, *PR on* partial remission on therapy, *PR off* partial remission off therapy, *R* relapse, *NR* no response, *F/U* follow-up, *d/c* discontinue, *mo* months, *d* days, *pts* patients, *NM* not mentioned, *IIF* indirect Immunofluorescence, *ELISA* Enzyme linked immunosorbent assay, *Dsg1 and Dsg3* desmoglein 1 and 3^a^Duration on medication included the time period on medication prior to the start of follow-up to this paper^b^Not mentioned whether on medication or notTable 5MethotrexateAuthor/yearType of study*N*\
M/FAge range/mean (years)Type of pemphigus vulgarisPrevious RxDuration of disease before MTXMTX dose1234567Lever and Goldberg et al. \[[@CR69]\]/1969Case series*N* = 5 \
M/F = 4/126--79MucocutaneousPred11 mo to 7 years25--150 mg/weekJablonska et al. \[[@CR70]\]/1970Case series*N* = 1032--83 (mean = 58.8)NMPred, triamcinoloneNM25 mg/weekPiamphongsant and sivayathorn et al. \[[@CR71]\]/1975Case series*N* = 333--48 (Mean = 43.8)NMPred, MTX in 1 ptNM12.5--25 mg/weekLever and Schaumburg-Lever, Lever et al. \[[@CR72], [@CR73]\]/1977Case series*N* = 4120--79 (mean = 51)MucocutaneousNoneNM20--50 mg/weekMashkilleyson et al. \[[@CR74]\]/1988Case series*N* = 5326--75 (mean = 56)NMPredNM25--50 mg/weekSmith and Bystryn et al. \[[@CR75]\]/1999Case series*N* = 9 M/F = 8/1Mean = 59NMPredNM12.2 mg/week (13 courses)Baum et al. \[[@CR76]\]^b^/2012Retrospective study*N* = 30NMNMNMNM15 mg/weekAuthor/yearDuration to initial improvement in symptoms after MTXFollow up periodConcomitant RxOutcomeDuration on medication (MTX)^a^PV antibody titer changes after RxAdverse effects891011121314Lever and Goldberg et al. \[[@CR69]\]/1969NM5--7 yearsPredCR on = 4, improvement = 1. additional details NMPred d/c in 1 patientt at fifth year. Tapered in rest on clinical improvement. MTX continued In all patients at end of f/uIIF: Pt1---1:640 to 1:80 to 1:10 to neg\
Pt2**---**1:40 to 1:10\
Pt3**---**1:40 to 1:10\
Pt4**---**1:20 to 1:40 to 0\
Pt5**---**1:80 to 1:40 to 0 to 1:10Nausea, lassitudeJablonska et al. \[[@CR70]\]/19701--30 weeksNMPred, triamcinoloneImprovement in 8/9 pts after 1--30 weeks of treatment. Death = 1 due to bronchopneumonia. Whether PR or CR---NMDuration of MTX 1--7.5 mo. MTX discontinued in six patients due to its side effectsNMBronchopneumonia, cerebral thrombosis, septicemia, bronchitis, anemia, diarrhoea, leucopenia, bacterial infectionPiamphongsant and sivayathorn et al. \[[@CR71]\]/1975NMNMPredDeath = 1 due to Pred side effects; CR on = 2Duration of MTX 33--78 days maintenance dose contd at end of f/uNMNMLever and Schaumburg-Lever, Lever et al. \[[@CR72], [@CR73]\]/1977NM11--15 yearsPrednisone = 40--360 mg/dayDeath = 4 unrelated to MTX; CR on = 8, PR on = 15, CR off = 14MTX D/c in 14 pts with CR off therapy, mean duration of f/u after d/c of medication was mean 2.6 years (3 mo to 8 years) without any relapse. Rx contd in others at end of f/uNMNausea, leucopenia, pyodermaMashkilleyson et al. \[[@CR74]\]/19882--3 daysNMPredNot effective in nine patients, CR on = 31; PR on = 11MTX discontinued in two patients due to its side effectsNMPneumonia, exacerbation of gastric ulcer, pyoderma, moniliasis, necrtotizing gingivitis, TB of larynxSmith and Bystryn et al. \[[@CR75]\]/1999NMNMPrednisone = 3--40 mg/dayCR on = 6 pts within 6 mo of start of therapy. Additional details NMPred d/c in 6 pts within 6 mo after start of MTX therapy. MTX continued in all as flare-ups were seen within 23 days of discontinuing MTX at end of f/uNMNausea, mild elevations of transaminaseBaum et al. \[[@CR76]\]^b^/2012NMNMPredImprovement in 21 pts at 6 mo of treatment. Additional details NMPred dose taperedNMMild adverse effects*Pred* prednisone, *MTX* methotrexate, *CR off* complete remission off therapy, *CR on* complete remission on therapy, *PR* partial remission, *PR on* partial remission on therapy, *PR off* partial remission off therapy, *R* relapse, *NR* no response, *F/U* follow-up, *d/c* discontinue, *mo* months, *d* days, *pt* patient, *NM* not mentioned, *IIF* indirect immunofluorescence, *Dsg1 and Dsg3* desmoglein 1 and 3^a^Duration on medication included the time period on medication prior to the start of follow-up to this paper^b^Only abstract is available for Baum et al. \[[@CR75]\]/2012Table 6RituximabAuthor/yearType of study*N*\
M/FAge range/mean (yrs)Type of pemphigus vulgarisPrevious RxDuration of disease before RtxRituximab dose1234567Salopek et al. \[[@CR77]\]/2002Case report1/F29MucocutaneousPred, AZA, Pulsed iv CyclP, Pl, IVIg, MMF9 mo375 mg/m^2^ BSA---6 infusions over 8 weeksCooper et al. \[[@CR78]\]/2002Case report1/M54CutaneousPred, AZA, MMF, Pl, IVIg, CyclP20 mo375 mg/m^2^ BSAonce weekly for 4 weeksEspana et al. \[[@CR79]\]/2003Case report1/M39MucocutaneousPred, AZA, Pl, CyclPNM375 mg/m^2^ BSAonce weekly for 4 weeksMorrison et al. \[[@CR80]\]/2004Case report1/M51MucocutaneousPred, MTX, Dapsone, AZA, minocycline, IVIg MMF, CyclP56 mo375 mg/m^2^ BSAonce weekly for 4 weeksMorrison et al. \[[@CR80]\]/2004Case report1/M37CutaneousCyclP, Pred, Pl, Dapsone, IVIg70 mo375 mg/m^2^ BSAonce weekly for 4 weeksMorrison et al. \[[@CR80]\]/2004Case report1/F47MucocutaneousAZA, MMF, IVIg, CyclP,30 mo375 mg/m^2^ BSA once weekly for 4 weeksVirgolini Marzocchi \[[@CR25]\]/2007Case report1/F53CutaneousPred, CyclP, MTX120 mo375 mg/m^2^ BSA once weekly for 4 weeksWenzel et al. \[[@CR81]\]/2004Case report1/F55CutaneousPred, AZA, CyclP, MTX, MMF, IVIg156 mo600 mg (corresponding 375 mg/m^2^ BSA) once weekly within 5 weeksDupuy et al. \[[@CR82]\]/2004Case report1/F34MucocutaneousPred, CyclP144 mo(375 mg/m^2^ BSA once weekly for 4 weeks) ×2 at 6 mo intervalDupuy et al. \[[@CR82]\]/2004Case report1/F42MucocutaneousAZA, MTX, Pred, MMF, IVIg, extracorporeal photopheresis cyclosporine60 mo(375 mg/m^2^ BSA once weekly for 4 weeks) ×2 at 6 mo intervalDupuy et al. \[[@CR82]\]/2004Case report1/M20CutaneousPred, dapsone, gold compounds, MMF, IVIg, Pl24 mo375 mg/m^2^ BSA once weekly for 4 weeksKong et al. \[[@CR83]\]/2005Case report1/F17MucocutaneousPred, AZA, MMF, MP, IVIg, Pl84 mo375 mg/m^2^ BSA once weekly for 4 weeksArin et al. \[[@CR34]\]/2005Case report1/F60MucocutaneousPred, MMF, AZA8 years375 mg/m^2^ BSA once weekly for 4 weeksArin et al. \[[@CR34]\]/2005Case report1/F26MucocutaneousPred, MMF, AZA, MTX3 years375 mg/m^2^ BSA once weekly for 4 weeksArin et al. \[[@CR34]\]/2005Case report1/F27MucocutaneousPred, MMF, AZA, MTX3 years375 mg/m^2^ BSA once weekly for 4 weeksArin et al. \[[@CR34]\]/2005Case report1/F57MucocutaneousPred, MMF, AZA14 years375 mg/m^2^ BSA once weekly for 4 weeksSchmidt et al. \[[@CR84]\]/2005Case report1/M14MucocutaneousPred, AZA. Dapsone, MMF, CyclP, staphyloccocal protein A immunoadsorption2.5 years375 mg/m^2^ BSA once weekly for 4 weeksSchmidt et al. \[[@CR85]\]/2006Case report1/F17MucocutaneousPred, IVIg, AZA, MMF, MTX30 mo375 mg/m^2^ BSA once weekly for 4 weeksSchmidt et al. \[[@CR85]\]/2006Case report1/F39MucocutaneousPred, IVIg, AZA79 mo375 mg/m^2^ BSA once weekly for 4 weeksSchmidt et al. \[[@CR85]\]/2006Case report1/F68MucocutaneousPred, IVIg, MMF, dexamethasone-cyclP pulse64 mo375 mg/m^2^ BSA once weekly for 4 weeksSchmidt et al. \[[@CR85]\]/2006Case report1/F81MucocutaneousDexamethasone-cyclP pulse7 mo375 mg/m^2^ BSA once weekly for 4 weeksAhmed et al. \[[@CR86]\]/2006Case series*N* = 11 M/F = 5/615--68MucocutaneousPred, MMF, AZA, MTX, Dapsone, Gold,CyclP,Cyclosporine, colchine, tacrolimus31--219 mo (mean = 68.8 mo)375 mg/m^2^ BSA once weekly for 3 weeks; fourth week---IVIg; 10 infusions of Rtx in 9 ptsGoh et al. \[[@CR87]\]/2007Open label pilot study*N* = 5 \
M/F = 3/246--62/57MucocutaneousAZA, MMF, IVIg, Pl, iv cyclP, cyclosporine, gold2--96 mo375 mg/m^2^ BSA once weekly for 4 weeksMarzano et al. \[[@CR88]\]/2007Case series*N* = 3 \
M/F = 2/1Pt1: 51\
Pt2: 50\
Pt3: 55MucocutaneousAZA, MMF, IVIg, Pred, CyclPPt 1: 6 years;\
Pt 2: 5 years;\
Pt 3: 4 years375 mg/m^2^ BSA once weekly for 4 weeks; 2 more infusions for pt 3 (one each mo)Antonucci et al. \[[@CR89]\]/2007Case series*N* = 5 \
M/F = 4/128--35Mucocutaneous = 2\
Cutaneous = 3AZA, MMF, IVIg, Pred, CyclP, MTX Pl, Cyclosporine3--7 years375 mg/m^2^ BSA once weekly for 4 weeksCianchini et al. \[[@CR90]\]/2007Case series*N* = 10 \
M/F = 5/527--63MucocutaneousPred, AZA, MMF, Pl, CyclP, cyclosporine, extracorporeal photopheresis1--9 years375 mg/m^2^ BSA once weekly for 4 weeks. Additional Rtx infusion in only one patientJoly et al. \[[@CR91]\]/2007Case series*N* = 14 \
M/F = NMMean = 53.7MucocutaneousPred, IVIg, AZA, MTX, MMF, cyclosporine4--168 mo (mean = 70.2 mo)375 mg/m^2^ BSA once weekly for 4 weeksShimanovich et al. \[[@CR92]\]/2007Case series*N* = 5 \
M/F = 1/437--71MucocutaneousPred, AZA, MMF, Pl, MTX, cyclosporine, Cyclp dexamethasone, dapsone3--76 mo375 mg/m^2^ BSA once weekly for 4 weeksEming et al. \[[@CR93]\]/2008Case series*N* = 11 \
M/F = 5/637--70/52.1Mucocutaneous = 7, mucosal = 2; cutaneous = 2Ped, AZA, MMFNM375 mg/m^2^ BSA once weekly for 4 weeksFaurschou and Gniadecki \[[@CR94]\]/2008Case report1/M68MucocutaneousPred, MMF, IVIg3 years(375 mg/m^2^ BSA once weekly for 4 weeks) ×2 at 6 mo intervalFaurschou and Gniadecki \[[@CR94]\]/2008Case report1/F46MucosalPred, MTX, MMF, IVIgNM(375 mg/m^2^ BSA once weekly for 4 weeks) × 2 at 6 mo intervalPfutze et al. \[[@CR95]\]/2009Case series*N* = 5 \
M/F = 2/3Mean = 55Mucosal dominantCS, MMFNM375 mg/m^2^ BSA once weekly for 4 weeksFuertes et al. \[[@CR96]\]/2010Case report1/M1.5MucocutaneousPred, AZA, Cyclosporine, Dapsone, GoldNewly diagnosedMucocutaneousKasperkiewicz et al. \[[@CR97]\]/2011Pilot study*N* = 17 \
M/F = 8/938--75/mean = 55Mucocutaneous = 7; mucosal = 6; cutaneous = 4AZA, cyclosporine, CyclP, MTX, MMF, dapsone, IVIg, PAIA, Pl, Pred, dexamethasone, hydroxychlorquine3--144 moTwo infusions of 1000 mg 2 wks apart. Additional Rtx cycle in 2 ptsCraythorne et al. \[[@CR98]\]/2011Case series*N* = 6 \
M/F = 3/345--71MucocutaneousPred, AZA, MMF, cyclosporine0--13 years375 mg/m^2^ BSA once weekly for 8 weeks then monthly ranging from 4 to 10 mo in all ptsKasperkiewicz et al. \[[@CR99]\]/2011Case series*N* = 8 \
M/F = 4/443--65Cutaneous = 1; Mucosal = 7AZA, MMF, Pred, dapsone, cyclosporine, dexamethasone3--72 mo375 mg/m^2^ BSA once weekly for 4 weeks = 3 pts; 1000 mg twice 2 wks apart = 5Kim et al. \[[@CR100]\]/2011Retrospective study*N* = 25 PV + 2 PF\
M/F = 12/1324--83Mucocutaneous = 20; cutaneous = 3; mucosal = 2AZA, MMF, IVIg, CyclP, steroid pulse therapy, cyclosporine12--15.5 mo(375 mg/m^2^ BSA once weekly)2 wks11 pts3 wks11 pts4 wks1 pt5 wks2 ptsReguiai et al. \[[@CR101]\]/2011Case series*N* = 9 \
M/F = 3/614--61MucocutaneousPred, IVIg, AZA, MMFNM375 mg/m^2^ BSA once weekly for 4 weeksHorvath et al. \[[@CR102]\]/2011Case series*N* = 12 \
M/F = 8/434--80MucocutaneousAZA, Pred, MMF, dapsone, doxyycline, CyclP, IVIg, dexamethasone, nicotinic acid, mycophenolic acid2--12 yearsTwo Rtx infusions of 500 mg at interval of 2 weeks in 10 pts and at an interval of 4 and 3 weeks in 2 ptsFeldman et al. \[[@CR103]\]/2011Retrospective analysis*N* = 19 \
M/F = 14/5Mean = 52Mucocutaneous = 14; mucosal only = 5Pred with or without immunosuppressive agentNM375 mg/m^2^ BSA once weekly---12 infusions over 6 mo periodLeshem et al. \[[@CR104]\]/2012Case series*N* = 42 PV + 3 PF18--83Mucosal only = 40Pred, MTX, AZA, IVIg, Dapsone, Rtx (lymphoma protocol), CyclP0--163 mo (mean = 25 mo)Two infusions of 1000 mg 2 wks apartCianchini et al. \[[@CR37]\]/2012Case series*N* = 37 PV + 5 PF\
M/F = 13/2927--75Mucous or mucocutaneous involvement. No's NMPred, immunosuppressants1--13 years; (mean = 4.2 years)Two infusions of 1000 mg 2 wks apart. Additional 500 mg Rtx infusion on PR or no response 6 mo after initial infusionLunardon et al. \[[@CR105]\]/2012Case series*N* = 24 \
M/F = 13/1126--86/50MucocutaneousPred, AZA, MMF, Dapsone, CyclP, IVIg, Cyclosporine3--234 mo (mean = 41 mo)(375 mg/m^2^ BSA once weekly for 4 weeks) ×13 pts. (Two infusions of 1000 mg 2 wks apart) × 11 pts.\
1 Rtx cycle = 6 pts\
2 Rtx cycle = 8 pts\
3 Rtx cycle = 7 pts\
4 Rtx cycle = 2 pts\
6 Rtx cycle = 1 ptKasperkiewicz and Eming et al. \[[@CR106]\]/2012Case series*N* = 33 PV + 3 PF\
M/F = 16/2015--76/52Mucosal = 29Pred, AZA, MMF, Pl, MTX,PAIA, IVIg, CyclP, chloroquine, leflunomide0.1--16 years (mean = 4)4 × 375 mg/m^2^ = 9 pts.\
2 × 1000 mg = 25 pts.\
Two cycles of 4 × 375 mg/m^2^ = 1 pt.\
7 × 375 mg/m^2^ = 1 ptBalighi et al. \[[@CR107]\]/2013Phase 2 clinical trial*N* = 40 \
M/F = 33/740--50MucocutaneousPred, AZA, MMF, Dapsone, IVIg, CyclPMean = 35 ± 32 mo375 mg/m^2^ BSA once weekly for 4 weeksKanwar et al. \[[@CR108]\]/2013Open label pilot study*N* = 9 \
M/F = 5/49--60MucocutaneousPred, AZA, dapsone, dexamethasone pulse4--72 mo (mean = 18 mo)375 mg/m^2^ BSA once weekly for 4 weeks = 1 pt;\
Two infusions of 1000 mg 2 wks apart = 7 pts; 1 × 1000 mg + 1 × 140 mg = 1 ptKolesnik et al. \[[@CR109]\]/2014Case series*N* = 6 \
M/F = 3/348--81MucocutaneousPred, AZA, MMF, Dapsone, PAIA, Rtx in 1 pt1--240 mo375 mg/m^2^ BSA once weekly for 3 to 6 weeks in combination with PAIAHeelan et al. \[[@CR35]\]/2014Case series*N* = 84 PV + 8 PF\
M/F = 37/5513--77/43Mucocutaneous = 61, mucosal = 20, cutaneous = 11Pred, AZA, MMF, IVIg, MTX, dapsone, CyclP, gold, cyclosporine, cyclosporine, mycophenolate sodium0--256 (mean = 24 mo)Two infusions of 1000 mg 2 wks apart; 1000 or 500 mg 6 mo or more after induction if requiredKanwar et al. \[[@CR110]\]/2014Randomized, comparative, observer-blinded study*N* = 15 \
M/F = 8/7Mean = 33 yearsMucocutaneousDexamethasone pulse therapy, AZA, Pred, IVIg, MMF0.3--6 yearsHigh dose grp: Two infusions of 1000 mg 2 wks apart = 7 pts; Low dose grp: Two infusions of 500 mg 2 wks apart = 8 ptsOjami et al. \[[@CR111]\]/2014Case series*N* = 14 \
M/F = 7/730--75 (mean = 54.3)Mucosal = 14;MMF, AZA, PredNMTwo infusions of 1000 mg 2 wks apart; 375 mg/m^2^ BSA once weekly for 4 weeksAuthor/yearConcomitant RxDuration to initial improvement in symptoms after RtxFollow up periodOutcomeDuration on medication (Rituximab and previous)^a^PV Antibody titer changes after Rx (U ml^−1^)Adverse effects891011121314Salopek et al. \[[@CR77]\]/2002Pred 1 mg/kg daily92 days after last infusionAfter Rtx = 6.3 mo, total = 18.9 moPR occasional minor flare ups18.9 mo. Rx continued with IVIg and CyclP at end of f/u1:4000 to 0 at 5 mo after first infusion; and at 8 mo from 0 to 1:1000NMCooper et al. \[[@CR78]\]/2002Pred, MMFIn 2 weeks after first infusionAfter Rtx = 6 mo, total = 26 moPR. Clinical improvement20 mo. Pred tapered over 3 mo; MMF d/c after 4 mo of start of therapyIIF: No change in titer. Stable at 1:1280NMEspana et al. \[[@CR79]\]/2003Pred6 weeks after first infusion40 weeksCR onDuration on medication NM. Pred tapered; AZA d/c before Rtx infusionAnti Dsg1: 77 to 7; Anti Dsg3: 160 to 90 at 28 wks., ICS = 1:160 to 1:10NMMorrison et al. \[[@CR80]\]/2004Pred, CyclP4 wks after first infusion 95 % re-epithelizationAfter Rtx = 18 moCR on. Mean duration of medication use before taper to low dose was 18 mo66 mo. Pred d/c 9 mo after Rtx; CyclP d/c 10 mo after RtxIIF: 1:2560 to 1:640 to 1:40 in 10 moNMMorrison et al. \[[@CR80]\]/2004CyclP, IVIg, Pred4 mo after last infusion---free of all lesionsAfter Rtx = 4 mo, total = 52 moDeath in 5 mo after Rtx from Pneumocystis carinii pneumonia6 years. IVIg d/c before starting Rtx; Pred and Cyclp were not changed and contd at end of f/uIIF: 1:320 to 1:160Pneumocystis carinii pneumoniaMorrison et al. \[[@CR80]\]/2004CyclPAfter last infusion and contd to improve over next 9 moAfter Rtx = 9 mo; total = 35 moPR39 mo and CyclP d/c twice but restarted and contd at low doses at end of f/uIIF: 1:2560 to 1:640 to 1:320NMVirgolini Marzocchi \[[@CR25]\]/2007Pred, CyclP3 mo after last infusion complete healing of lesionsAfter Rtx = 10 mo; total = 130 moCR on within 3 mo of start of therapyAbout 121 months.NMNoneWenzel et al. \[[@CR81]\]/2004PredBetween second and sixth wk after last infusionAfter Rtx = 3 moCR on159 mo and Rx contd. With prednisone at end of f/uIIF: 1:640 to 1:40NoneDupuy et al. \[[@CR82]\]/2004Pred, AZAthird wk after first infusion improvement was noticed. second course due to worsening of lesionsAfter Rtx = 9.8 mo, total = 35 moNo significant improvement152 mo. Pred tapered by fifth mo after first infusion but increased again due to flare up and maintainedIIF: 1:500 to 1:200Community acquired pneumonia after first course. None after second courseDupuy et al. \[[@CR82]\]/2004Pred, MMF cyclosporineFirst course: improvement from second wk after first infusion; second course: improvement in 3 wks after first infusionAfter Rtx = 17 mo, total = 77 moCR within 4 mo after first course with a flare up at sixth mo; after second course CR on therapy at 6 mo of therapyPred tapered from week 10 after first infusion but increased again during second course due to flare upIIF: first course: 1:200 to 0 in 2 mo to 1:500 in 11 mo\
second course: 0 in 6 moFacial edema, P aeruginosa hip arthritisDupuy et al. \[[@CR82]\]/2004PredClinical improvement observed from week 7 after starting Rtx infusionAfter Rtx = 9 mo, total = 33 moCR on within third month after first Rtx infusion30 mo and Pred tapered and contd. at sixth mo after Rtx therapy at end of f/uIIF: 1:1600 to 1in 3 mo and 0 until end of F/UNMKong et al. \[[@CR83]\]/2005PredClinical improvement in 10 days after starting RtxAfter Rtx = 17 mo, total = 101 moCR offTotal duration on medication = 101 mo. 17 mo of Rtx therapy. Pred tapered over 2 wks after 10 days of remarkable improvement on Rtx therapy and d/c. But maintenance infusions of Rtx contd every 8--12 weeks at end of f/uAnti Dsg 1: 1:2079 to 1:33 Anti Dsg3: 1:4616 to 1:564NMArin et al. \[[@CR34]\]/2005Pred, MMFNMAfter Rtx = 24 mo; total = 120 moCR onMedication given for 10 years and MMF continued at end of f/uAnti Dsg1: 0--20\
Anti Dsg3: 100 to 75 to 100 againNo serious events. Nausea, vomiting, chills or cough, facial edemaArin et al. \[[@CR34]\]/2005Pred, MTXNMAfter Rtx = 10 mo; total = 46 moPRMedication given for 46 mo and MTX + Pred contd at end of f/uAnti Dsg1: 15 to 0 to 15\
Anti Dsg3: 100 to 0No serious events. Nausea, vomiting, chills or cough, facial edemaArin et al. \[[@CR34]\]/2005Pred, MTXNMAfter Rtx = 10 mo; total = 46 moPRMedication given for 46 mo and MTX + Pred contd at end of f/uAnti Dsg1: 20 no change\
Anti Dsg3: 100 to 75 to 100 againNo serious events. Nausea, vomiting, chills or cough, facial edemaArin et al. \[[@CR34]\]/2005Pred, MMFNMAfter Rtx = 36 mo; total = 204 moCR onMedication given for 17 years and Pred contd at end of f/uAnti Dsg1: 200 to 100\
Anti Dsg3: 175 to 8No serious events. Nausea, vomiting, chills or cough, facial edemaSchmidt et al. \[[@CR84]\]/2005Pred, MMF, IVIg (after first and fourth infusion)Improvement 10 wks after first infusion and CR in 9 moAfter Rtx = 24 mo; total = 54 moCR offMedication given for 4.5 years. Pred and MMF d/c after 18 and 21 mo of starting Rtx therapy, respectivelyAnti Dsg3 and Dsg1: 875 to 0 in 7 mo and stable at 0 after thatHypergammaglobulinemia after 1st infusionSchmidt et al. \[[@CR85]\]/2006Pred, MMFPR after 6 mo of RtxAfter Rtx = 7 moPRMedication given for 37 mo. MMF + Pred contd at end of f/uELISA: Anti Dsg3: 7708 to 517NoneSchmidt et al. \[[@CR85]\]/2006AZA, PredPR after 3 mo of RtxAfter Rtx = 21 moPRMedication given for 100 mo. AZA + Pred contd at end of f/uELISA: Anti Dsg3: 806 to 108NoneSchmidt et al. \[[@CR85]\]/2006MMF, PredPR after 3 mo of RtxAfter Rtx = 9 moCR onMedication given for 73 mo. MMF contd at end of f/uELISA: Anti Dsg3: 877 to 27NoneSchmidt et al. \[[@CR85]\]/2006Dexamethasone-cyclP pulsePR after 3 mo of RtxAfter Rtx = 68 moCR off at 12 mo F/URx d/c after 12 moELISA: Anti Dsg3:222 to 0 Anti Dsg1:985 to 0Bacterial pneumonia, pulmonary embolismAhmed et al. \[[@CR86]\]/2006NMWithin 3--6 wks (mean = 4 wks)After Rtx = 15--37 mo; (mean 32.5 mo)CR off = 9 within 7--9 wks after Rtx infusion between seventh and ninth infusion; *R* = 2 at 6 mo after tenth Rtx infusion and recent CR in 15 and 24 mo respMedication given for mean 50.6 mo (range = 31--225 mo) and prednisone continued at end of f/uAntikeratinocyte antibodies: reduced from Mean 1:1280 (1:5120 to 1:320) to 1:40NoneGoh et al. \[[@CR87]\]/2007Pred, AZA, MMF, cyclosporineClinical response ranged between 2 and 8 moAfter Rtx = 13--18 moCR off = 1 CR on = 2 PD = 2; CR within 13--18 mo after start of Rtx therapyMedication given for 2--114 mo. Rx d/c after 13 mo of start of therapy in CR off ptIIF: 1:1280, 1:60,1:10, to 0 in 16 to 18 mo after Rtx in all 5 ptsTransient fatigue in 3 pts, neutropenia, community acquired pneumoniaMarzano et al. \[[@CR88]\]/2007PredPt 1: 2 wks after last rtx infusion. Pt 2: 5 mo after last Rtx infusion. Pt 3: 3 mo after first Rtx infusion, total 6 Rtx infusions for third ptPt 1: 24 mo;\
Pt 2: 21 mo;\
Pt 3: 2 moPt 1: CR on;\
Pt 2: PR;\
Pt 3:MR (minimal response)Medication given for 8 years (Pt1), 6.8 years (Pt2), 4.2 years (Pt3) and Rx continued in all patients at end of f/uPt1: Anti Dsg1---125 to 0; Anti Dsg3---175 to 125. Pt2: Anti Dsg1---50 to 0; Anti Dsg3---225 to 25 at end of F/U. Pt3: NMFacial edema, chills, precordial pain only in first and second infusionAntonucci et al. \[[@CR89]\]/2007PredPt1: 2 wks after last rtx infusion; Pt2: 4 wks after last Rtx infusion. Pt3: 3 wks afterlast Rtx infusion Pt4: 8 wks after first Rtx infusion Pt5: 5 wks after last Rtx infusionAfter Rtx = 11--13 moPt 1: R after 12 mo of CR; CR off again after second cycle of Rtx with no relapse\
Pt2: CR off in 4 weeks after Rtx therapy Pt3: CR on Pt4: CR off in 12 mo after Rtx therapy Pt5: CR onPt1: 6--7 years. Pred d/c 1 mo after end of Rtx therapy. Pt2: 4.1 years. Pred tapered and d/c after 1 mo of Rtx. Pt 3: 4.1 years. Pred tapered and contd. Pt4: 8 years. Pred d/c in 10 weeks Pt5: 3.2 yearsELISA: Anti Dsg 3: Pt1: 200 to 60 in 24 mo Pt2: 200 to 55 in 24 mo Pt3: 200 to 60 in 24 mo Pt4: 180 to 175 in 48 mo Pt5: 200 to 100 in 24 moNoneCianchini et al. \[[@CR90]\]/2007Pred, AZA, CyclPNM16--18 moCR on within 6 mo after Rtx infusion = 2\
CR on within 2 mo after Rtx infusion = 2\
CR on within 1 mo after Rtx infusion = 2\
CR on within 1 yr after Rtx infusion = 2\
PR within 6 mo after Rtx infusion = 2Medication given for 1.1--9.1 years. Prednisone maintenance dose continued in all patients at end of f/uAnti Dsg1:\
Pt1:125-0 in 18 mo Pt2: stable at 0\
Pt3: 175-10 in 12 mo\
Pt4: 150-0 in 12 mo\
Pt5: 200-100 in 12 mo Pt6: 240-140 in 6 mo pt7: 260-75 in 6 mo Pt8: 250-0 in 6 mo Pt9: 210-75 in 6 Pt10: 25-0 in 6 mo Anti Dsg3: Pt1: 290-75 in 18 mo Pt2: 175-0 in 18 mo Pt3: 120-0 in 15 mo Pt4: 140-25 in 15 mo Pt5: 120-25 in 15 mo Pt6: 200-50 in 6 mo Pt7: 150-0 in 6 mo Pt8: 100-25 in 6 mo Pt9: 200-50 in 6 mo Pt10: 140-60 in 6 moTachycardia in one patientJoly et al. \[[@CR91]\]/2007Prednisone in all but 3 ptsNM26--45 mo (mean = 34 mo)CR on = 14 PV pts within 3 mo in 12 pts; within 6 mo in 1 pt; within 12 mo in 1 pt\
R in 6 pts after a mean of 18.9 mo. CR at end of F/U in 18/21 pts with PV and PFMedication given for (range = 4--213 mo) mean 52.1 mo. Corticosteroids tapered by 10 % twice a month after Rtx started controlling disease. 8/21 pts with PV and PF d/c RxReduction in 9/14 pts with CR. High titers even on CR in 5 ptsHeadache, asthenia, fever, chills, nausea, pyelonephritisShimanovich et al. \[[@CR92]\]/2007PAIA, IVIgWithin 4 weeks of Rx13--30 mo2 pts failed to show improvement with Rtx who improved on subsequent IVIg; CR on = 4; CR off = 1 within 6 mo of start of therapyMedication given for 6 mo up to 106 mo Rx d/c within 6 mo of start of therapy in CR off ptELISA: Anti Dsg1: Negative in all 5 pts at end of F/U\
Anti Dsg3:\
Pt1: 465-neg in 27 mo Pt2: 1179-40 in 30 mo Pt3: 1170-44 in 21 mo Pt4: 257-neg in 13 mo Pt5: 230-23 in 27 mo*Staphylococcus aureus* bacteremia, deep venous thrombosis, *P. carinii* pneumonia. Resolved with appropriate managementEming et al. \[[@CR93]\]/2008PrednisoneWithin 6 mo after Rtx therapy\>12 mo in 10 pts. 3 mo in 1 ptBetween 6 and 12 mo of Rtx therapy CR on = 8 and *R* = 3Pred tapered acc to clinical response. MMF or AZA given for 6 mo after Rtx and tapered acc to clinical remissionAnti Dsg3 IgG:\
100 to 25 in 12 mo in 8 CR pts\
60 to 25 in 6 mo to 75 in 12 mo in 3 R ptsNMFaurschou and Gniadecki \[[@CR94]\]/2008Pred, MMF6 wks after first Rtx infusion6 mo after second courseCR on after second course which was 6 mo after first courseMedication given for 3.8 years. Pred tapered, MMF continued at end of f/uIIF: 1:1280 to 1:640NMFaurschou and Gniadecki \[[@CR94]\]/2008Pred3 wks after first Rtx infusionTotal = 4 yearsCR on after second course which was 6 mo after first courseMedication given for 4 years. Pred tapered, MMF continued at end of f/uNMNMPfutze et al. \[[@CR95]\]/2009Pred, MMF1 mo and 6 mo after Rtx therapy in 4 and 1 pt resp. And improved over 12 moAfter Rtx = 12 moCR on = 5 within 12 mo of start of therapyPred tapered and d/c by 12 mo. MMF continued at end of f/uAnti Dsg1:40 ± 9.5 % to 6.1 ± 11.5 % in 12 mo\
Anti Dsg3:44 ± 34.7 % to 8.3 ± 22.1 % in 12 moNMFuertes et al. \[[@CR96]\]/2010None1 mo after start of Rtx therapyAfter Rtx = 18 mo; total = 16 yearsCR off started within 6 mo of start of Rtx therapy. No relapseNo other drugs other than RtxAnti Dsg1: reduced to 2U/ml. Anti Dsg3: reduced to 11 U/mlNoneKasperkiewicz et al. \[[@CR97]\]/2011PAIA, AZA, MMF, dexamethasone pulsesMean 2.7 wks after therapy11--43 mo; mean = 29 moPR = 2; MD = 1; CR on = 8; CR off = 6; R before CR = 4. CR within mean 8.4 moMedication given for 3--183 mo. d/c of Rx in 6 CR off pts in 6--39 mo. Rx continued in rest others at end of f/uAnti Dsg 1 and 3: Mean: 100 to 0 at last testing of F/UNMCraythorne et al. \[[@CR98]\]/2011ImmunosuppressantNM20--35 moCR off = 6 within 5--20 weeks of start of therapyMedication given for 1 mo to 13.2 years Immunosuppressant withdrawnNMNausea, cough, chillsKasperkiewicz et al. \[[@CR99]\]/2011AZA, CyclP, MMF, Pred, Dexamethasone, clobetasol propionate, IVIg, PAIANM12--59 mo/mean = 24.9 moCR off = 6 within 12--59 mo(mean 18.6 mo); CR on = 1 within 26--28 mo(mean 5.4 mo); PR = 1 within 27 mo; R in 9--24 mo after first Rtx infusion before CR = 4Medication given for 3--99 mo. Rx d/c in 12 mo in 3 CR off pts. Rx contd in others at end of f/uAnti Dsg1 and 3: Decreased by 49--100 % (mean 90 %) at end of F/UDyspnea, hypotonia, vomitingKim et al. \[[@CR100]\]/2011NM4 wks after last Rtx infusion3--43 mo; mean = 15.7 moCR off = 16 within 186 days; PR = 5 within 135 days; *R* = 8 within 11.5 mo F/U in pts with 2 Rtx infusions. Death = 1Medication given for 3 mo to 71 mo.Anti Dsg1: 176.2--18.9\
Anti Dsg3: 189.2--66.3NoneReguiai et al. \[[@CR101]\]/2011PrednisoneWithin 3 mo after Rtx cycle.After Rtx = 12--71 mo (mean = 41 mo); total = 81 moCR on minimal therapy for mean 27 mo after last Rtx cycle = 4; CR under Pred 3 mo after last Rtx cycle = 1. CR off, mean duration of f/u after d/c of medication was 31 mo after last Rtx cycle = 4Pred discontinued 12 mo after last Rtx cycleModerate to high titers of Abs even though pts were in CR in 6/9 ptsNoneHorvath et al. \[[@CR102]\]/2011Mycophenolic acid, AZA, Pred, MMFWithin 2--24 weeks (median = 7 weeks)32--152 weeks (mean = 94)PR on = 4; PR off = 2; CR on = 3; CR off = 3; *R* = 5 (CR within 36 wks after re-treatment). CR in median 51 wks, PR in 34.5 median wksMedication given for 2--13.5 years. Rx d/c in CR off pts at 39--64 weeksAnti Dsg3: Decreased in all but Relapsed pts. Anti Dsg1: 5 pts with positive titers before Rx showed decrease. \*One pt with CR off had high titers throughout the Rx periodNausea, fatigue, neutropenia, sepsis, herpes zoster, flu like symptomsFeldman et al. \[[@CR103]\]/2011IVIgNMLong term CR pts = 29.6 ± 11.2 mo; R = 40 ± 7 moLong term CR pts off = 11; R = 8 (total 15 relapses) retreatment in R grp lead to long term CRPred and immunosuppressive agents tapered and d/c long before Rtx therapy endedAnti Dsg1 levels increased during relapse in pts with mucocutaneous lesionsNMLeshem et al. \[[@CR104]\]/2012Pred, AZA, MMFMean within 4 mo of first Rtx cycleMean = 18 ± 12 moNo Remission = 4. PR on = 5; PR off = 2; CR on = 15; CR off = 19; CR in median time of 1--4 mo after start of therapyMedications given for 0--181 mo. d/c in few months after achieving CRNMInfusion reaction with first Rtx infusion cycle which could be managed wellCianchini et al. \[[@CR37]\]/2012PredNM12--51 mo (mean = 26.5 mo)PR = 6; CR on = 7; CR off = 29; (CR within 30--150 days, mean = 70 days); *R* = 20 within 8--64 mo (CR in all PR and R pts with additional 500 mg infusion of Rtx 6 mo after initial infusion)Medications given for 1--14 years. Immunosuppressant d/c with start of Rtx therapy. Pred tapered graduallyNMNoneLunardon et al. \[[@CR105]\]/2012Pred, AZA, MMF, Dapsone, CyclP, MTX, IVIgNM12--80 moPR on = 7; PR off = 3; CR on = 3; CR off = 11; CR in mean 19 moMedication given for 3--251 mo. Concomitant drugs d/c after first Rtx infusionData of only 10 pts available. Titer decreased by median---80 %Perirectal phlegmon and intrapelvic abscesses in one ptKasperkiewicz and Eming et al. \[[@CR106]\]/2012Pred, AZA, MMF, MTX,PAIA, IVIgNM1--37 mo (mean = 11)No response = 2; PR = 11; CR on = 20Medications given for 0.1--16.6 yearsAnti Dsg1: returned to normal in 14/24 pts\
Anti Dsg3: returned to normal in 11/32 ptsInfusion related reactions, allergic reactions and infectionsBalighi et al. \[[@CR107]\]/2013Pred1--20 week. At mean 6.35 weeks3--46 mo. (mean = 12 mo)Initial PR = 21, CR on = 19, *R* = 21 in mean 8 mo\
Final, CR = 40 within mean 10.13 mo (between 0.5 and 23 mo) after start of therapyMedication given for 3--46 mo after starting Rituximab. Duration on medication before Rituximab: NM. All immunosuppressant d/c 1 week prior to start of Rtx therapy. Pred tapered gradually as per improvementNMLung abscess, deep vein thrombosis, pneumonia, sepsis, cavernous sinus thrombosis, generalized arthralgia, Steven Johnson's syndromeKanwar et al. \[[@CR108]\]/2013Pred in 8 pts, P + MMF in one ptWithin 5 weeks (5--12 weeks)24--48 weeks. (Mean = 33.4 weeks)Death due to sepsis = 1; PR on = 2; CR on = 3; CR off = 3; CR within mean 8 weeks after start of therapyMedications given for 2--21 mo. D/c in 8 weeks in CR off ptsELISA Index values: Anti Dsg1: Pt1: 1372-0.12 Pt2: 327-0.73; Pt3: 34.69- 10.01; Pt3: 32.55-2.2; Pt4: 1517.2-23.05; Pt5: 95.7-0; Pt6: 117.3-14.15.\
Anti Dsg3: Pt1:888-42; Pt2: 872-82; pt3: 1162-3; pt4: 124-132; Pt5: 63-0.97; Pt6: 25-0; pt7: 839-138Infusion related angioedema and sepsisKolesnik et al. \[[@CR109]\]/2014PAIA, Pred, AZA, DapsoneWithin first 4 weeks of therapy0--45 mo (mean = 22 mo)PR = 1; CR on = 4, mean duration of therapy use before taper to low dose was 3 to 12.5 mo; CR off = 1, mean duration of f/u after d/c of medication was 34 mo, No relapse. CR within 6.6 mo after first Rtx infusionMedications given for 1--252 moAnti Dsg1: decreased by 3--85 %\
Anti Dsg3: decreased by 0.3--107 %NoneHeelan et al. \[[@CR35]\]/2014Prednisone, immunosuppressant agentsNM45--78 mo (mean = 51 mo)PR on = 2; CR on = 26; CR off = 64; mean duration of f/u after d/c of medication was 51 mo with multiple R transformed into CR on retreatment. Median time to *R* = 15 moMedications given for 0--334 moNMNo serious events. Infusion reactionsKanwar et al. \[[@CR110]\]/2014AZAWithin 4--16 weeks48 weeksPR = all 15 pts in 4 to 24 wks; R in 4 high dose grp pt and 7 low dose grp pt in 32--36 wks of therapy; CR off = all 15 pts mean duration of f/u after d/c of medication was 4--40 wks subsequent to PR without relapseMedications given for 0.3 to 7 years. All Immunosuppressant agents d/c 4 weeks prior to Rtx therapyELISA Index values: High Dose grp:\
Anti Dsg1: 400 to 150 in 48 wks; Anti Dsg3: 90 to 20 in 48 wks\
Low dose grp:\
Anti Dsg1: 310 to 60 in 48 wks\
Anti Dsg3: 180 to 70 in 48 wksMild Infusion reaction, upper respiratory infection, diarrhea, striae, acneiform eruptionsOjami et al. \[[@CR111]\]/2014MMF, PredWithin 3 moNM*R* = 1; Controlled (PR) = 9 within 3--24 mo after start of therapy; CR on = 4 within 24--36 mo of start of therapyMedications given for 0.4--10 years. Pred tapered to 10 mg/dayNMPost infusion febrile reaction*Rtx* rituximab, *Pred* prednisone, *AZA* azathioprine, *IVIg* intravenous immunoglobulin, *CyclP* cyclophosphamide, *Pl* plasmapheresis, *MTX* methotrexate, *CR off* complete remission off therapy, *CR on* complete remission on therapy, *PR* partial remission, *PR on* partial remission on therapy, *PR off* partial remission off therapy, *CI (PR)* clinical Improvement (PR) on doses greater than minimal therapy, *R* relapse, *NR* no response, *F/U* follow-up, *d/c* discontinue, *mo* months, *d* days, *pts* patients, *NM* not mentioned, *IIF* indirect immunofluorescence, *ELISA* enzyme linked immunosorbent assay, *Dsg1 and Dsg3* desmoglein 1 and 3^a^Duration on medication included the time period on medication prior to the start of follow-up to this paper

Definitions for some of the terms relating to treatment outcomes listed in the tables are described in a consensus statement published in 2008 \[[@CR10]\] as follows:

*Complete remission off therapy*: Absence of new and/or established lesions while the patient is off all systemic therapy for at least 2 months.

*Complete remission on therapy*: Absence of new or established lesions while the patient is receiving minimal therapy.

*Minimal therapy*: Less than, or equal to, 10 mg/day of prednisone (or the equivalent) and/or minimal adjuvant therapy for at least 2 months.

*Minimal adjuvant therapy*: Half of the dose required to be defined as treatment failure.

*Failure of therapy*: Failure to control disease activity (i.e., relapse/flare) with full therapeutic doses of systemic treatments.

*Partial remission off therapy*: Presence of transient new lesions that heal within 1 week without treatment and while the patient is off all systemic therapy for at least 2 months.

*Partial remission on minimal therapy*: Presence of transient new lesions that heal within 1 week while the patient is receiving minimal therapy, including topical steroids \[[@CR10]\].

However not all papers included in this review have described their specific definition for these terms. If these terms were mentioned in the publication, we have listed them in the tables as mentioned in the publication.

This article is based on previously conducted studies and does not involve any studies of human or animal subjects performed by any of the authors.

Results {#Sec3}
=======

Corticosteroids (CS) {#Sec4}
--------------------

Since the time of their approval in the 1950s, corticosteroids have been the mainstay of treatment of PV.

### Mechanism of Action {#Sec5}

Corticosteroids have strong anti-inflammatory and immunosuppressive effects. They affect almost every aspect of the immune system. They are potent inhibitors of NFkappa B activation and have effects on leukocyte movement, leukocyte function, and humoral factors. In addition they have inhibitory effects on many known cytokines \[[@CR11]\].

The first case series on corticosteroid use in PV was published in 1972.

The publications reporting use of corticosteroids in PV are summarized in Table [1](#Tab1){ref-type="table"}. This table includes papers that had systemic corticosteroids as the primary medication used. Topical steroids were also used in many of the reports. In addition, adjuvant drugs were added in most cases. These adjuvants included azathioprine, methotrexate, cyclophosphamide, dapsone, gold, levamisole, cyclosporine, and mycophenolate. Adjuvants were usually administered one at a time; however, they were changed when lack of response was noted, and therefore some patients had multiple adjuvants used sequentially over the period of treatment.

### Publication Type, Patient Profiles, and Sample Sizes {#Sec6}

Seventeen case series were found, with the number of cases included in the individual papers ranging from 4 to 1111 cases (a total of 1704 patients were included in the 17 case series, of which 1681 had PV and 23 had either pemphigus foliaceous, pemphigus vegetans, or pemphigus erythematous). Six case reports describing single patients, one prospective cohort study (*n* = 74), two randomized controlled trials (*n* = 20 and *n* = 120), and five retrospective cohort studies (*n* = 15, *n* = 16, *n* = 23, *n* = 32, and *n* = 154) are summarized in the Table [1](#Tab1){ref-type="table"}. In all, the total number of cases in these 31 publications was 2164 out of which 2141 were PV patients, and the rest had pemphigus foliaceous or pemphigus vegetans or pemphigus erythematous. These 31 reports originated from the USA, Israel, Iran, Sri Lanka, India, Scotland, Italy, Greece, Spain, the Netherlands, Germany, France, Singapore and Turkey.

Age at initial diagnosis of PV in these publications ranged from 4 to 89 years.

### Medication Use {#Sec7}

Prednisone and prednisolone were the most commonly used corticosteroids. Starting doses ranged from 15 to 180 mg prednisone equivalent daily in all but one of the reports where doses as high as 400 mg daily were used \[[@CR12], [@CR13]\].

### Duration of PV Before Corticosteroids Were Started {#Sec8}

This ranged from 0.15 months to 6 years.

### Duration of Total Follow-up {#Sec9}

Duration of total clinical follow-up of the individual patients ranged from 9 months to 22 years.

### Duration Before Any Clinical Improvement Was Noted {#Sec10}

Seven publications reported on the duration before any clinical improvement after the start of corticosteroids was apparent, and this ranged from 3 days to 19 weeks \[[@CR14]--[@CR20]\].

### Duration to Start of Taper of Corticosteroids {#Sec11}

Information regarding tapering of corticosteroids was reported in seven publications. The duration before the start of taper of corticosteroids ranged from 0.5 to 12 months in these seven publications comprising of 156 patients.

### Duration to Complete Remission (On and Off Therapy) {#Sec12}

Duration to complete remission on therapy was reported in 15 articles, and ranged from 1.5 to 42 months (3.5 years), in 797 patients.

Duration to complete remission off therapy was reported in 15 articles, and ranged from 4 to 120 months (10 years) in 321 patients.

### Remission {#Sec13}

Of a total of 2141 patients reported on in Table [1](#Tab1){ref-type="table"}, at the end of follow-up 97 patients had achieved partial remission on therapy, 797 patients had achieved complete remission on therapy, and 321 patients had achieved complete remission off therapy. A total of 485 patients were still being treated at the time of publication, 156 patients were lost to follow-up, death occurred in 177 patients, and 47 patients were classified as non-responders and referred elsewhere for treatment.

### Duration of Medication Use {#Sec14}

Total duration of medication use for all reported patients including those still on therapy at the time of publication ranged from 1.5 to 240 months (20 years).

### Follow-up Duration After Discontinuation of Medications {#Sec15}

Follow-up ranged from 2 to 156 months (13 years) after discontinuation of treatment in the 321 patients with complete remission off therapy, during which time there was no recurrence.

### Mortality {#Sec16}

Death occurred in a total of 177 of 2141 patients (8.26 %) with PV in all reports. These included deaths from all causes. Of these, the reports published between 1970 and 1980 included 127 patients with 61 deaths (48.03 %), between 1981 and 1990 included 183 patients with 26 deaths (14.2 %), between 1991 and 2000 included 190 patients with 7 deaths (3.6 %), and those published between 2001 and 2010 included 1589 patients with 83 deaths (5.2 %).

### Adverse Effects {#Sec17}

Adverse effects from corticosteroids reported in these papers included Cushingoid symptoms, diabetes mellitus, osteoporosis, hypertension, insomnia, GI upset, increased weight, candidiasis, tuberculosis, mood change, abnormal liver function test, fungal and viral infection, fatigue, acute psychosis, hyperglycemia, electrolyte imbalance, hypocalcemia, acidosis, hyperkalemia, phlebitis, herpes simplex, hyperlipidemia, bone marrow depression, cataract, and myopathy.

Azathioprine (AZA) {#Sec18}
------------------

Azathioprine was approved by the US Food and Drug Administration (FDA) in 1968 as an immunosuppressant to prevent organ transplant rejection.

### Mechanism of Action {#Sec19}

This drug restricts synthesis of DNA, RNA, and proteins by inhibiting metabolism of purine. It also interferes with cellular metabolism and mitosis \[[@CR8]\].

### Publication Type, Patient Profiles, and Sample Sizes {#Sec20}

The studies reporting use of AZA in PV are summarized in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. Of the 31 papers in Table [1](#Tab1){ref-type="table"}, 17 had included azathioprine as one of the treatment modalities. Table [2](#Tab2){ref-type="table"} includes only those publications that reported on comparative analyses of outcomes for patients on prednisone alone vs. those on prednisone in combination with azathioprine. The first case series on use of AZA in PV was published in 1986.

One randomized double blind controlled study (*n* = 56) and two retrospective cohort studies (*n* = 48 and *n* = 36) are summarized in Table [2](#Tab2){ref-type="table"}. In all, a total of 140 patients were included in these three reports.

Age at initial diagnosis of PV in these publications ranged from 16 to 83 years.

### Medication Use {#Sec21}

The dosage of azathioprine used was 40 mg/day up to 3 mg/kg/day in all reports. Prednisone was used concomitantly with azathioprine in all reports. Azathioprine was added at the onset of treatment in the three reports in Table [2](#Tab2){ref-type="table"} and sometime after onset of corticosteroid use in the reports in Table [1](#Tab1){ref-type="table"}.

### Duration of PV Before Azathioprine Was Started in the Reports Summarized in Table [2](#Tab2){ref-type="table"} {#Sec22}

This ranged from 4 to 10 months.

### Duration of Follow-up in the Reports Summarized in Table [2](#Tab2){ref-type="table"} {#Sec23}

Duration of clinical follow-up of the individual patients on azathioprine in these reports ranged from 12 months to 10 years.

### Duration to Complete Remission (On and Off therapy) for the Azathioprine Plus Prednisone Group in Table [2](#Tab2){ref-type="table"} {#Sec24}

Duration to complete remission on therapy was reported in three articles and, ranged from 6 to 12 months, in 67 patients.

Duration to complete remission off therapy was reported in two articles and, ranged from 6 to 12 months, in eight patients.

Patients on prednisone and azathioprine had better responses as compared to patients on prednisone alone, with more patients achieving remission, and with fewer side effects.

### Remission {#Sec25}

Of a total of 140 patients, at the end of follow-up 11 patients had achieved partial remission and mean duration to achieve that was 234.4 days, 67 patients had achieved complete remission on therapy, and eight patients had achieved complete remission off therapy. Six patients were still being treated at the time of publication. No response was seen in 17 patients. Treatment failed in five patients. Death occurred in 13 patients and 13 patients were lost to follow-up.

### Adverse Effects Reported in Table [2](#Tab2){ref-type="table"} {#Sec26}

Adverse effects in patients on azathioprine and corticosteroids reported in these publications included leukopenia, anemia, thrombocytopenia, pancytopenia, hepatotoxicity, hypertension, gastrointestinal problems, lethargy, weight gain, muscle weakness, adrenal suppression, alopecia, and rash-like skin disorders.

Mycophenolate Mofetil (MMF) {#Sec27}
---------------------------

Mycophenolate Mofetil was approved by the FDA in 1995 as an immunosuppressant to prevent organ transplant rejection.

### Mechanism of Action {#Sec28}

After oral administration, mycophenolate is absorbed rapidly and then gets converted to the active metabolite mycophenolic acid (MPA). This active metabolite inhibits inosine monophosphate dehydrogenase selectively and hence inhibits de novo pathway of purine synthesis in T and B cells, which results in inhibition of T and B cell proliferation \[[@CR20]\].

Publications reporting use of MMF as an adjuvant to corticosteroids in PV were included in Table [1](#Tab1){ref-type="table"}. Additional papers which have reported on the use of mycophenolate in patients with refractory PV (previous treatment with corticosteroids and azathioprine was unsuccessful in achieving remission) are summarized in Table [3](#Tab3){ref-type="table"}. Of 31 papers in Table [1](#Tab1){ref-type="table"}, three had included MMF as one of the treatment modalities.

### Publication Type, Patient Profiles, and Sample Sizes {#Sec29}

The first case series on use of MMF in PV patients was published in 1999.

Four case series were included, with the number of cases included in the individual papers ranging from 9 to 31 cases (a total of 64 patients in four case series); two were case reports describing single patients and two were randomized prospective trials (*n* = 94 and *n* = 21, respectively). One additional randomized clinical trial enrolled both PV and PF patients \[*n* = 36 (PV) + 11 (PF); results were not reported separately for the PV and PF patients in this study\] and one retrospective analysis (*n* = 18) is summarized in the tables. The total number of patients treated with MMF in these 10 reports was 247.

Age at initial diagnosis of PV in these publications ranged from 6 to 78 years.

### Medication Use and Duration of PV Before MMF Was Started {#Sec30}

Medication use and duration of PV before MMF was started ranged from 1 month to 14 years. During this period patients were on a combination of corticosteroids and azathioprine. At the time mycophenolate was added, the azathioprine was discontinued; however, the patients continued to be on corticosteroids. One publication (Powell et al.) reported on patients in whom multiple medications like methotrexate, cyclophosphamide, IVIg, dapsone, gold, thalidomide, and minocycline along with azathioprine and corticosteroids were tried prior to addition of mycophenolate \[[@CR21]\].

The starting dosage of mycophenolate mofetil used was 2--3 g/day in all reports.

### Duration of Follow-up {#Sec31}

Duration of clinical follow-up of the individual patients after the start of MMF therapy ranged from 5 to 130 months.

### Duration Before Any Clinical Improvement Was Noted {#Sec32}

First improvement in lesions was noted after 2--24 weeks after addition of mycophenolate to the existing medication regimen.

### Duration to Complete Remission (On and Off Therapy) After Addition of MMF {#Sec33}

Duration to complete remission on therapy was reported in six articles and, ranged from 2 to 16 months, in 104 patients.

Duration to complete remission off therapy was reported in one article and, ranged from 24 to 36 months, in 17 patients.

### Remission {#Sec34}

Of a total of 247 patients, 104 patients achieved complete remission on therapy and 17 patients achieved complete remission off therapy. A total of 76 patients achieved partial remission, and the duration to achieve that ranged from 129 to 150 days after the start of therapy. Failure of MMF was mentioned in four reports (*N* = 176) in 18 patients who were referred for treatment with rituximab or IVIg. Two patients were still being treated at the time of publication, 29 patients were lost to follow-up or withdrawn from study, and death occurred in one patient.

### Adverse Effects {#Sec35}

Adverse effects in patients on mycophenolate and corticosteroids reported in these publications included gastrointestinal problems, myalgia, neutropenia, and lymphopenia, which were the most common side effects reported. Headache, increased fasting blood glucose level, and hypertension, nausea, depression, pyrexia, redistribution of body fat, eye disease, weight gain, fatigue, and arthralgia were also reported.

In the one publication where enteric coated mycophenolate sodium was used, the side effects reported were headache and increased fasting blood glucose level.

Intravenous Immunoglobulin (IVIg) {#Sec36}
---------------------------------

IVIg was approved by the FDA for primary immune deficiency in 1952 \[[@CR22]\].

### Mechanism of Action {#Sec37}

Intravenous immunoglobulins (IVIg) are obtained from a plasma pool of thousands of donors \[[@CR22]\].

These immunoglobulins neutralize and slow down the production of circulating pemphigus antibodies \[[@CR23]\].

### Publication Type, Patient Profiles, and Sample Sizes {#Sec38}

The studies reporting use of IVIg in PV are summarized in Table [4](#Tab4){ref-type="table"}. The first case series on IVIg in PV was published in 2002.

One case series (*n* = 6), two case reports describing single patients, and one randomized placebo-controlled double-blind trial (*n* = 40) are summarized in Table [4](#Tab4){ref-type="table"}, with a total of 48 patients included in these four papers. These reports included patients previously treated with corticosteroids, cyclophosphamide, azathioprine, and methotrexate without adequate response, prior to start of IVIg.

Age at initial diagnosis of PV in these publications ranged from 41 to 78 years.

### Medication Use {#Sec39}

The dosage of IVIg used was 400 mg/kg/day for 5 days followed by long- or short-term single doses of 400 mg/kg/day every 6 weeks for 6 months to 1 year. Concomitant drugs mainly used were corticosteroids in the published studies.

### Duration of PV Before IVIg Was Started {#Sec40}

This ranged from 2 months to 5 years.

### Duration of Total Follow-up {#Sec41}

Duration of total clinical follow-up of the individual patients ranged from 2 months to 2 years.

### Duration Before Any Clinical Improvement Was Noted {#Sec42}

First improvement in lesions was reported within 2--3 weeks of first IVIg infusion in all 48 patients.

### Duration to Start of Taper of Corticosteroids {#Sec43}

Only one case series of six patients described the duration to the start of taper of corticosteroids and only mentioned that the median time was 16 days after the start of IVIg infusions.

### Duration to Complete Remission (On and Off Therapy) {#Sec44}

This information was not available from the publications. However, all reports discussed improvement in all patients treated with IVIg; in six patients this was achieved within 3 weeks and in 29 patients within 3--12 months. Thirteen patients in the placebo group had no improvement.

### Adverse Effects in Patients on IVIg Reported in Table [4](#Tab4){ref-type="table"} {#Sec45}

Headache, abdominal discomfort, nausea, constipation, lymphopenia, hepatitis C, and palpitations.

Methotrexate {#Sec46}
------------

Methotrexate was approved by the FDA for psoriasis in 1971 and for rheumatoid arthritis in 1988.

### Mechanism of Action {#Sec47}

Methotrexate inhibits the metabolism of folic acid and is used as a chemotherapeutic and immunosuppressive agent. Methotrexate allosterically inhibits dihydrofolate reductase, which plays a role in tetrahydrofolate synthesis. As folic acid is essential for normal cell growth and replication, methotrexate is effective against malignant cell growth and has anti-inflammatory effects \[[@CR24]\].

### Publication Type, Patient Profiles, and Sample Sizes {#Sec48}

The studies reporting use of methotrexate in PV are summarized in Table [5](#Tab5){ref-type="table"}. The first case series on MTX in PV was published in 1969.

Publications reporting use of methotrexate in PV were included in Table [1](#Tab1){ref-type="table"} (7 of 31 papers included methotrexate), and additional papers that reported on the use of methotrexate as the initial adjunctive treatment to corticosteroids are summarized in Table [5](#Tab5){ref-type="table"}.

Six case series were included, with the number of cases included in the individual papers ranging from 3 to 53 cases (total of 121 patients in six case series), and one retrospective cohort study (*n* = 30) are summarized in the tables. In all, a total of 151 patients treated with MTX are reported in seven studies.

Age at initial diagnosis of PV in these publications ranged from 20 to 83 years.

### Medication Use {#Sec49}

The dosage of MTX used in these publications ranged from 12.5 to 150 mg/week. Concomitant drug used along with methotrexate was prednisone.

### Duration of PV Before Methotrexate Was Started {#Sec50}

This ranged from 11 months to 7 years.

### Duration of Follow-up {#Sec51}

Duration of clinical follow-up of the individual patients after the start of MTX ranged from 5 to 15 years.

### Duration Before Any Clinical Improvement Was Noted {#Sec52}

First improvement in lesions was reported within 1--30 weeks after the start of methotrexate therapy.

### Duration to Complete Remission (On and Off Therapy) {#Sec53}

Duration to complete remission on therapy was reported in six articles and, ranged from 1 to 30 weeks, in 51 patients.

Duration to complete remission off therapy was reported in one article and, ranged from 3 months to 8 years, in 14 patients.

### Remission {#Sec54}

Of a total of 151 patients, at the end of follow-up, 56 patients had achieved partial remission and the duration to achieve that was within 6 months after the start of MTX therapy; 51 patients had achieved complete remission on therapy; and 14 patients had achieved complete remission off therapy. Twelve patients were lost to follow-up. Treatment was not effective in nine patients. Death unrelated to MTX occurred in six patients.

### Adverse Effects in Patients on MTX Reported in Table [5](#Tab5){ref-type="table"} {#Sec55}

Nausea, leukopenia, GI upset, fatigue, bacterial infection, bronchopneumonia, septicemia, necrotizing gingivitis, diarrhea, and pyoderma.

Rituximab {#Sec56}
---------

Rituximab was approved in 1997 by the FDA to treat B cell non-Hodgkin lymphoma and in 2006 to treat rheumatoid arthritis.

### Mechanism of Action {#Sec57}

Rituximab is a human--mouse chimeric monoclonal antibody to CD20 antigen on B cells. CD20 is a membrane protein that is involved in activation and proliferation of B cell \[[@CR25]\].

### Publication Type, Patient Profiles, and Sample Sizes {#Sec58}

The studies reporting use of rituximab in PV are summarized in Table [6](#Tab6){ref-type="table"}. The first case series on PV treated by rituximab was published in 2002.

Publications which have reported on the use of rituximab in patients with refractory PV (previous treatment with corticosteroids, azathioprine, methotrexate, mycophenolate, IVIg, and cyclophosphamide were unsuccessful in achieving remission) are summarized in Table [6](#Tab6){ref-type="table"}.

Nineteen case series were included, with the number of cases included in the individual papers ranging from 3 to 84 cases (total of 339 patients in 19 case series), 24 were case reports describing single patients, three open label pilot studies (*n* = 5, *n* = 9, and *n* = 17), one randomized prospective trial (*n* = 15), two retrospective analysis (*n* = 25 and *n* = 19), and one phase 2 clinical trial (*n* = 40) are summarized in the tables. In all, a total of 493 patients were treated with rituximab.

Age of patients treated with rituximab for PV in these publications ranged from 15 to 86.

### Medication Use {#Sec59}

The dosage of rituximab used was 375 mg/m^2^ body surface area (BSA) once weekly for 4 weeks or two infusions of 1000 mg at 2 weeks apart. Previously failed treatments before rituximab were prednisone, MMF, AZA, IVIg, MTX, dapsone, CyclP, plasmapheresis, protein A immunoadsorption, cyclosporine, dexamethasone, and gold. Concomitant drug used was prednisone, MMF, AZA, and IVIg.

### Duration of PV Before Rituximab Was Started {#Sec60}

This ranged from 1 months to 23 years.

### Duration of Follow-up {#Sec61}

Duration of clinical follow-up of the individual patients after the start of rituximab therapy ranged from 6 to 80 months.

### Duration Before Any Clinical Improvement Was Noted {#Sec62}

First improvement in lesions was reported within 2 weeks to 8 months after the first rituximab infusion.

### Duration to Complete Remission (On and Off Therapy) {#Sec63}

Duration to complete remission on therapy was reported in 32 articles and, ranged from 1 to 36 months, in 184 patients.

Duration to complete remission off therapy was reported in 22 articles and, ranged from 2 to 59 months, in 229 patients.

### Remission {#Sec64}

Of a total of 493 patients reported in Table [6](#Tab6){ref-type="table"}, at the end of follow-up, 80 patients had achieved partial remission, and duration to achieve that ranged from 3 to 27 months; 184 patients achieved complete remission on therapy; and 229 patients achieved complete remission off therapy. Death due to sepsis occurred in three patients. Relapses were seen in nine patients. No response to rituximab was seen in 11 patients. However, these patients had response after addition of IVIg or additional cycles of rituximab.

### Adverse Effects in Patients on Rituximab Reported in Table [6](#Tab6){ref-type="table"} {#Sec65}

Local pain, nausea, cough, chills, sepsis, and angioedema related to infusion.

Other Medications {#Sec66}
=================

Other Less Commonly Used Adjuvants from Studies Listed in Table [1](#Tab1){ref-type="table"} {#Sec67}
--------------------------------------------------------------------------------------------

*Gold salts* These are widely used in treatment of rheumatoid arthritis. Their action is related to their T cell-mediated immunosuppressive properties \[[@CR23]\].

*Plasmapheresis* This is used for removing antibodies from the circulation. Reduction in antibodies triggers production of new antibodies as a result of a feedback mechanism \[[@CR23]\].

*Immunoadsorption* With plasmapheresis protective immunoglobulins, albumin, and clotting factors are removed along with harmful pemphigus antibodies. Immunoadsorption selectively traps the harmful pemphigus antibodies through the sulfhydryl filtering membrane. Thus, protective antibodies and plasma components are returned \[[@CR23]\].

*Cyclophosphamide* It has been widely used in the treatment of cancer and also as an immunosuppressant. This drug is converted in the liver to its active metabolites aldophosphamide and phosphoramide mustard. These bind to DNA and inhibit its replication, which leads to cell death. It can be given orally as well as intravenously. One report described cyclophosphamide use in seven patients for treating PV in combination with corticosteroids and azathioprine \[[@CR26]\].

*Nicotinamide and tetracycline* These were used as steroid-sparing agent in combination with corticosteroids and azathioprine in one study of six patients with PV. Their mechanism of action is unclear \[[@CR27]\].

Discussion {#Sec68}
==========

In this paper, we have summarized the published literature on the management of PV. The published papers were mostly case reports, case series, observational studies, and only eight randomized controlled trials.

As a result of the relative rarity of pemphigus, published randomized trials are limited, which makes it difficult to evaluate the efficacy of different treatment regimens in this disease. This also precludes conduct of a meta-analysis. A Cochrane review published in 2009 concluded that "there is inadequate information available at present to ascertain the optimal therapy for pemphigus vulgaris" \[[@CR28]\]. While this remains the case, a summary of the literature provides information on disease course and prognosis as well as medication options, treatment responses, and side effects, which are of relevance to clinicians who treat this disease and patients who suffer from it.

The treatment options for PV have increased over the years. The early publications from the 1970s reported use of high corticosteroid doses over prolonged intervals and significant associated side effects. Later reports on PV management described use of corticosteroids along with steroid-sparing adjuvants, which allows a reduction in the total dose of corticosteroids used over the course of the treatment with a reduction in observed morbidity. The more commonly used steroid-sparing medications in the published reports include azathioprine, methotrexate, and mycophenolate mofetil. More recently, IVIg and rituximab have been used, mainly in patients with recalcitrant PV.

Overall, the mortality and morbidity from PV and the medications used in its treatment are considerably lower in the more recent publications than in the early reports.

The reported treatment response in patients with PV has varied significantly. Prognostic factors that have been identified include initial severity and extent of disease, with higher severity being predictive of poorer prognosis. \[[@CR29]\]. Perhaps related to this is the fact that early initiation of treatment before the disease becomes too severe or widespread has been associated with improved prognosis \[[@CR30], [@CR31]\]. Once treatment is initiated, good initial response to treatment has also been found to be indicative of a better prognosis \[[@CR32]\].

Most reports described medication courses of long duration before remission off therapy was achieved (between 5 and 10 years in the majority of patients with the range across all studies being 3 months to 27 years). However, Herbst and Bystryn described a group of 40 patients in whom 10 (25 %) patients achieved complete and long-lasting remission within 2 years of treatment; a subgroup of patients with PV, with a mild course of the disease requiring short courses of systemic medications or topical medication alone to induce remission \[[@CR5], [@CR32], [@CR33]\]; and at the other extreme a subgroup that is resistant to treatment and required high doses and prolonged therapy have also been described \[[@CR29], [@CR32], [@CR35]\].

The role of baseline laboratory tests, such as quantification of antibodies as predictors of disease course, has not been established. A recent study reported that a higher level of anti-Dsg1 autoantibodies (≥100 U/mL) at diagnosis was associated with poorer prognosis in univariate analyses; however, this did not remain significant after adjustment for age \[[@CR36]\].

Periodic antibody titers measured by indirect immunofluorescence or ELISA testing have not consistently shown correlation with clinical activity of PV \[[@CR37]\]. Most authors in the listed papers reported using clinical response alone to guide medication taper.

Reports using rituximab described remission off therapy in a shorter time frame (ranging from 2 months to 5 years) as compared to other medication combinations; this observation suggested that while the initial side effects may be significant, a shorter total duration of therapy may be possible with use of rituximab. Because rituximab is a more recent drug, first introduced in 1997, long-term side effects are not well characterized at this time.

Conclusion {#Sec69}
==========

The findings from this review emphasize the importance of early diagnosis of PV, early initiation of treatment, and use of a treatment regimen which includes a steroid-sparing adjuvant to allow a reduced total dose and duration on corticosteroids. For the majority of patients in these reports, a long-term course on medications lasting about 5--10 years was observed; however, subgroups of patients requiring shorter courses or those needing longer-term therapy were also described. In recent publications, commonly used initial regimens include corticosteroids in combination with mycophenolate or azathioprine; whereas, for patients with inadequate response to these regimens, adjuvants such as IVIG or rituximab were used \[[@CR21], [@CR38], [@CR39]\]. This review also highlights the need for more controlled trials to determine optimal treatment regimens for patients with PV.
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